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ABSTRACT 
Ayumi Nakamura: Molecular Mechanisms in the Developing and Maturing Brain 
(Under the direction of Mohanish Deshmukh) 
 
Neurons, unlike other cell types, persist throughout the entire lifespan of an 
organism. Additionally, neurons use multiple anti-apoptotic brakes during different stages 
of their life cycle in order to maintain their long-term survival. This dissertation 
investigates the role of two well-known anti-apoptotic genes, Bcl-xL and miR-29, which are 
believed to serve important functions in preventing cell death during embryonic brain 
development and during the period of postnatal brain maturation, respectively. Using 
conditional knockout mouse models of Bcl-xL and miR-29, I found that these genes may 
have additional non-apoptotic roles at different timepoints during the neuron’s life cycle, 
challenging the previously accepted roles of these genes.  First, I found that Bcl-xL, which is 
believed to be critical for brain development during the embryonic stages, was expressed 
at low levels in the rapidly dividing neuronal progenitor cells and was thus dispensable for 
the survival of these cells during embryonic development.  In contrast, the early 
differentiated postmitotic neurons acutely rely on Bcl-xL for their survival, the lack of 
which results in severe consequences in mice including microcephaly and neurobehavioral 
deficits such as hyperactivity, increased risk-taking and self-injurious behaviors.  Second, to 
probe the role of miR-29, a microRNA that is known to be critical for neuronal maturation 
by preventing apoptosis in neurons, I generated knockout mice that were conditionally 
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deleted for miR-29. We and other labs have predicted that the main role of miR-29 is to 
prevent apoptosis and that deleting miR-29 could lead to widespread neuronal death. 
Surprisingly, however, miR-29-deficient mice exhibit no signs of cell death in the brain. In 
contrast, we identified a novel function of miR-29 in governing DNA methylation, an event 
that has been primarily studied in the context of cancer and whose roles in the brain are 
just beginning to be uncovered.  I have found that miR-29 has an important epigenetic role 
in the brain via its ability to target the 3’ untranslated region (3’UTR) of a key DNA 
methyltransferase known as Dnmt3a. miR-29-deleted brains have increased levels of 
Dnmt3a, resulting in widespread hypermethylation across the genome. This, in turn, leads 
to transcriptional repression of multiple neuronal genes in the miR-29 knockout brains, 
resulting in severe neurobehavioral deficits including hyperactivity, hypersociability, 
excessive self-grooming and repetitive behaviors. Lastly, using RNAseq and gene 
association studies, I found that the pathways that are dysregulated in the miR-29-deleted 
mice are similar to those that are disrupted in the brains of patients with autism spectrum 
disorder (ASD), suggesting that miR-29 could be tested as a potential therapy in 
neurodevelopmental disorders in the future.  
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CHAPTER ONE: INTRODUCTION 
 
1.1 An overview of apoptosis  
Roles of the mammalian apoptotic pathway 
Apoptosis, a highly regulated pathway in which a cell is programmed to die, is 
critical for the maintenance of tissue homeostasis and for the maturation of various organs 
in the developing embryo (Jacobson et al. 1997). Cell death functions to eliminate cells that 
are no longer needed by the organism (Danial and Korsmeyer 2004). As a result, strict 
homeostasis is achieved between newly dividing cells and dying cells.  If apoptosis becomes 
dysregulated, various diseases can result including cancer, autoimmune and inflammatory 
diseases, as well as neurodegeneration and neuronal injury (Elmore 2007; Fuchs and 
Steller 2011). 
While the apoptotic pathway can be classified into different types, the process can 
also be categorized into pathological and physiological states (e.g. developmental apoptosis 
versus cancer and neurodegeneration). Physiological apoptosis plays a crucial role during 
embryogenesis. Failure to activate apoptosis in the organism results in embryonic lethality 
and severe central nervous system (CNS) defects, including hyperplasia of cells in the CNS, 
exencephaly (protrusion of brain matter from the skull), and incomplete neural tube 
closure (Kuida et al. 1996; Cecconi et al. 1998; Hakem et al. 1998; Kuida et al. 1998; Woo et 
al. 1998; Yoshida et al. 1998) (Fig. 1.1). Although the apoptotic pathway has been well 
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characterized in certain mammalian cell lines, exactly how cell death is regulated in the 
cells of the CNS remains largely unknown. 
   
The extrinsic pathway of apoptosis 
In mammalian cells, the two well-known mechanisms of activating apoptosis are via 
the extrinsic or intrinsic pathways (Tait and Green 2010).  The extrinsic pathway is 
engaged in certain cell types including immune cells in order to kill pathogen-infected cells 
and defective lymphocytes, thereby preventing autoimmunity and the development of 
tumors (Strasser et al. 2009). The extrinsic pathway involves the binding of ligands (e.g. 
Fas, TNF) to death receptors on the plasma membrane. This process leads to the activation 
of a protein known as caspase-8 and subsequently activates caspase-3, the major 
executioner caspase that mediates apoptosis, as discussed below (Tait and Green 2010) 
(Fig. 1.2). In this pathway, caspase-8 is also able to cleave a pro-apoptotic protein known as 
Bid into the truncated form of Bid (tBid), which then translocates from the cytosol to the 
mitochondria to engage the mitochondria to activate apoptosis (Strasser et al. 2009). 
 
The intrinsic pathway of apoptosis 
In the vast majority of other cells, various stimuli (e.g. growth factor deprivation, 
DNA damage, reactive oxygen species, and endoplasmic reticulum (ER) stress) activate 
apoptosis via the intrinsic pathway (Tait and Green 2010) (Fig. 1.2). Central to the intrinsic 
pathway of apoptosis is the permeabilization of the outer mitochondrial membrane, which 
releases cytochrome c (cyt c) and other apoptogenic proteins (apoptosis inducing factor, 
endonuclease G, Smac/Diablo) from the mitochondrial intermembrane space into the 
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cytosol (Saelens et al. 2004). While, for most of history, the mitochondria was referred to as 
the powerhouse of the cell, it was only in 1996 when Xiaodong Wang’s group made a 
seminal discovery that cyt c is released from the mitochondria during cell death (Liu et al. 
1996). Although in health cells, cyt c functions as a critical protein in the electron transport 
chain to carry out mitochondrial respiration to generate ATP via oxidative 
phosphorylation, cyt c also plays an essential role in mediating cell death upon its release 
into the cytosol.  
The release of cyt c from the mitochondria is strictly regulated by the Bcl-2 family of 
proteins (Jiang and Wang 2004). This family is composed of pro-apoptotic and anti-
apoptotic members, which are further sub-classified according to the number of Bcl-2 
homology (BH) domains contained within each protein (Fig. 1.3).  
 
Bax and Bak: The gatekeepers of the mitochondria  
Among the pro-apoptotic family members are the effector proteins Bax and Bak, 
which contain the BH1, BH2 and BH3 domains and are considered to be the gatekeepers of 
cyt c release (Wei et al. 2001).  In most healthy cells, Bax and Bak are maintained in a 
monomeric and inactive state (Walensky and Gavathiotis 2011). Upon an apoptotic 
stimulus, however, these proteins undergo a conformational change and oligomerize to 
form pores in the mitochondrial outer membrane and induce permeabilization of the 
membrane (a process known as mitochondrial outer membrane permeabilization, or 
MOMP) (Chipuk et al. 2006). MOMP thereby enables the release of cyt c from the 
mitochondria into the cytosol to activate the downstream apoptotic pathway.  
 
 4 
 
BH3-only proteins: Initial responders to apoptotic stimuli 
Another group of pro-apoptotic Bcl-2 family members known as the BH3-only 
proteins are composed of a single BH3 domain. These BH3-only proteins (Bid, Bim, Puma, 
Bik, Bad, Bmf, Hrk) respond to various apoptotic stimuli and are classified as either 
‘activators’ or ‘sensitizers’ (Lomonosova and Chinnadurai 2008; Chipuk et al. 2010). 
Activators (Bim, Bid, Puma) function by directly binding to and activating Bax and Bak, 
while sensitizers (Bmf, Bik, Hrk, Noxa) indirectly activate apoptosis by inhibiting the action 
of the anti-apoptotic Bcl-2 proteins (Youle and Strasser 2008; Martinou and Youle 2011). 
 
Anti-apoptotic Bcl-2 family members 
Finally, the release of cyt c requires not only the activation of the pro-apoptotic 
proteins Bax and Bak and their activation by the BH3-only proteins but also the inhibition 
of the anti-apoptotic members (e.g. Bcl-2, Bcl-xL, Bcl-w, Mcl-1), thus preventing cell death 
by inadvertent activation of a single pathway. These anti-apoptotic proteins normally 
prevent cell death by inhibiting Bax and Bak activity (Ow et al. 2008; Bogner et al. 2010). 
Anti-apoptotic Bcl-2 members contain four BH domains, BH1-BH4 (Kroemer 1997). This 
group of proteins has gained widespread attention in the cancer field where researchers 
have found that multiple tumors upregulate these anti-apoptotic proteins to evade cell 
death. Indeed, one of the exciting future directions in personalized medicine is to 
downregulate these proteins for tumor therapy. Interestingly, similar approaches are also 
being developed for tumors that evade cancer by downregulating pro-apoptotic BH3-only 
family members (Letai et al. 2002; Deng et al. 2007; Friedman et al. 2015). 
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Events downstream of the release of cyt c 
While the release of cytochrome c is a prerequisite for the intrinsic pathway of cell 
death, it is also considered to be a point of no return by most scientists in the cell death 
field. However, events after cyt c release are equally important, and any perturbations 
downstream of the mitochondria have significant effects.  Using a cell extract assay similar 
to the one that enabled the discovery of cyt c in the cell death pathway, Xiaodong Wang’s 
group identified a protein known as Apaf-1 (apoptotic protease activating factor 1). In fact, 
the key function of mitochondrially-released cyt c is to bind to and activate Apaf-1 (Danial 
and Korsmeyer 2004).  Apaf-1 contains a WD40 repeat domain that keeps the protein in an 
inactive conformation (Riedl and Salvesen 2007). The binding of cyt c to the WD40 domain 
induces a conformational change in Apaf-1 that exposes its caspase activation and 
recruitment domain (CARD), resulting in its association with and activation of caspase-9 
(Riedl and Salvesen 2007) (Fig. 1.4).  The Apaf-1/caspase-9 complex, called the 
apoptosome complex, activates caspase-3, which then cleaves specific cellular proteins to 
induce rapid cell death (Danial and Korsmeyer 2004).  Indeed, mutants of Apaf-1 that lack 
the WD40 domain are constitutively active and can activate caspase-3 in the absence of cyt 
c (Hu et al. 1998a; Hu et al. 1998b). In addition, in cell culture models that either inhibit the 
binding of cyt c to Apaf-1 (e.g. injecting yeast cyt c that cannot bind to Apaf-1) or 
inhibit/knock down Apaf-1, or inhibit capsase-3 activation (either by siRNA knockdown or 
by using chemical inhibitors such as QVD or z-VAD), these processes can prevent cell death 
and extend cell survival even in the presence of apoptosis-inducing drugs. 
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1.2 The apoptotic pathway is essential for embryonic development and survival  
Activation of apoptosis is critical for the development of the embryo, and failure to 
induce cell death leads to embryonic lethality with significant defects in various organ 
systems. One organ that critically relies on the cell death program during development is 
the nervous system (Yuan and Yankner 2000). The striking phenotypes of mutant mice that 
are defective in apoptosis point to the importance of cell death in the CNS (Kuida et al. 
1996; Cecconi et al. 1998; Hakem et al. 1998; Kuida et al. 1998; Woo et al. 1998; Yoshida et 
al. 1998). Mice that are deficient in Apaf-1, Caspase-9, or Caspase-3 are all embryonic or 
perinatally lethal and display hyperplasia of CNS tissue that results in exencephaly (Fig. 
1.1).  In particular, these mice exhibit an enlargement of the mitotic ventricular zone and 
expansion of the telencephalon (Kuida et al. 1996; Cecconi et al. 1998; Hakem et al. 1998; 
Kuida et al. 1998; Woo et al. 1998; Yoshida et al. 1998). In addition to these phenotypes in 
the CNS, mice deficient in the various apoptotic proteins display features such as a delay in 
the removal of interdigital webs of the forelimbs and hindlimbs that normally occurs in 
wildtype mice, and thymocytes isolated from these mutant mice also exhibit resistance to 
various apoptotic stimuli. 
 
1.3  Apoptotic mechanisms in the developing CNS  
Apoptosis is especially critical and is tightly regulated in the nervous system of a 
variety of organisms. Bob Horvitz’s group mapped out the cell fate of every cell in 
Caenorhabditis elegans (C. elegans) and found that exactly 131 cells undergo apoptosis 
during normal development. What is astonishing is that, of the 131 cells that are 
programmed to die, 105 are of neuronal origin (Sulston and Horvitz 1977; Sulston et al. 
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1983). These pioneering discoveries in C. elegans underscore the importance of 
maintaining the proper number of neurons during normal development. 
In mammals, the phenomenon of programmed cell death has historically been 
extensively investigated in the peripheral nervous system (PNS) where trophic factor 
deprivation is known to activate the mitochondrial pathway to match the number of 
innervating neurons with the size of its target tissue (De Zio et al. 2005). The apoptotic 
pathway has been particularly well studied in the sympathetic nervous system, in which 
sympathetic neurons rely on nerve growth factor (NGF) for survival. In contrast, very little 
is known about apoptotic mechanisms in the developing CNS. Unlike the PNS, the neurons 
of the CNS do not depend on a single trophic factor for their survival (Dekkers and Barde 
2013; Dekkers et al. 2013) (Fig. 1.5).  
The mechanisms underlying the survival and death of various neuronal subtypes, 
including the excitatory projection neurons and inhibitory interneurons in the CNS are 
virtually unknown. Recently, Arturo Alvarez-Buylla’s group discovered that inhibitory 
interneurons in the developing cortex utilize an intrinsic mechanism to undergo cell death 
independent of external cues (Southwell et al. 2012). Approximately 40% of interneurons 
in the postnatal brain were shown to die in a Bax-dependent mechanism. In addition, 
transplantation of embryonic interneuron precursors into the postnatal brain during the 
period when the endogenous interneurons usually undergo cell death revealed that 
apoptosis was activated in the transplanted population two weeks after they were 
generated. Southwell et al. also transplanted varying numbers of embryonic interneuron 
precursors into the postnatal brain. If the neurons were governed by the neurotrophic 
theory, in which cells compete for limiting target-derived growth factors for survival, 
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heterochronic transplantation of larger numbers of precursors would lead to greater 
numbers of dying interneurons. However, the proportion of cell death was similar across 
all transplant sizes, challenging the hypothesis that the survival of these CNS interneurons 
is governed by the neurotrophic theory. These findings have uncovered key features of 
apoptotic mechanisms that determine how cell death is regulated in the developing 
mammalian brain. 
 However, how the apoptotic pathway is controlled in the developing CNS must still 
be investigated further. In particular, the regulation of cell death by anti-apoptotic proteins 
raises interesting yet unanswered questions. Although mammalian cells express multiple 
anti-apoptotic Bcl-2 family proteins, including Bcl-2, Bcl-xL and Mcl-1, whether CNS 
neurons are acutely dependent on a single anti-apoptotic protein for their survival is 
currently unknown. In addition, which specific neuronal populations are dependent on Bcl-
xL and the consequence of the loss of this anti-apoptotic protein on neurobehavior has 
been unexplored. The work described in this thesis provides insight into how cell death in 
CNS neurons is regulated by Bcl-xL and sheds light on the essential function of Bcl-xL for 
the survival of neurons in the cortex that control complex behaviors. 
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1.4  DNA methylation: An overview  
 One of the epigenetic modifications that occurs in the mammalian genome is DNA 
methylation, which involves the addition of a methyl group on to a cytosine adjacent to a 
guanine (referred to as mCG) (Suzuki and Bird 2008; Smith and Meissner 2013). DNA 
methylation is a process that is well conserved in plants, fungi and mammals (Chan et al. 
2005; Goll and Bestor 2005; Henderson and Jacobsen 2007; Schubeler 2015) and is 
mediated by the DNA methyltransferase (DNMT) family of proteins (Denis et al. 2011; 
Jurkowska et al. 2011). DNA methylation is important for processes such as pluripotency 
and differentiation, embryonic development, genomic imprinting, X chromosome 
inactivation, chromatin modification and proper brain maturation (Jones 2012).  
DNA methylation is a modification that is generally associated with transcriptional 
silencing of genes (Suzuki and Bird 2008). At promoter regions, this process promotes 
transcriptional repression by directly blocking the ability of transcription factors to bind or 
by indirectly causing transcriptional silencing via the recruitment of methyl-binding 
domain-containing proteins and co-repressors such as histone deacetylases, which induce 
the formation of heterochromatin (Klose and Bird 2006; Lim and Maher 2010) (Fig. 1.6). In 
addition to promoter regions, gene bodies across the genome are also quite heavily 
methylated (Rabinowicz et al. 2003; Eckhardt et al. 2006). What is remarkable is that, 
unlike the inverse correlation between promoter methylation and gene transcription, the 
opposite relationship holds true for methylation patterns of gene bodies. Thus, the 
methylation of gene bodies is correlated with genes that are actively transcribed (Hellman 
and Chess 2007; Lister et al. 2009; Feng et al. 2010). However, the exact function of gene 
body methylation remains unknown.  
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1.5  Mediators of DNA methylation: The writers, readers and erasers 
The writers 
 The DNMTs are known to catalyze the transfer of a methyl group from S-
adenosylmethionine (SAM) to the C5 position of a cytosine on the DNA, a major process 
that underlies the epigenetic modification of DNA (Goll and Bestor 2005). To detect the 
methylation of cytosines throughout the mammalian genome, the gold standard protocol is 
to use bisulfite genomic DNA sequencing. Treatment of the DNA with sodium bisulfite leads 
to the deamination of unmethylated cytosine to uracil, while methylated cytosines are not 
prone to undergoing this chemical conversion (Li and Tollefsbol 2011) (Fig. 1.7). The 
information in the epigenome can then be sequenced using standard RNAseq analysis or 
other methods. 
The DNMT proteins are often classified into maintenance and de novo DNA 
methyltransferases. Dnmt1 was the first mammalian DNA methyltransferase discovered in 
mammals (Gruenbaum et al., 1982). Dnmt1is most highly expressed upon entry into the S 
phase of cell division in dividing cells and is localized to DNA replication foci (Leonhardt et 
al. 1992; Chuang et al. 1997). Dnmt1 plays a critical role in the transmission of pre-existing 
methylation patterns on the parental DNA to the daughter strands. Thus, during mitosis, 
the cytosines on the nascent DNA of daughter cells are recognized by Dnmt1, and the 
methylation pattern that is present on the parent strand and that already contains the 
methyl groups is propagated onto the nascent strand  (Chuang et al. 1997; Sharif et al. 
2007). As such, Dnmt1 is known as a maintenance DNA methyltransferase. In contrast, 
Dnmt3a and Dnmt3b are known as the de novo DNA methyltransferases, as they add 
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methyl groups to cytosines on unmethylated DNA strands during development (Okano et 
al. 1999).  
 Analyses of the DNMTs have revealed unique expression patterns of these proteins 
throughout embryonic and postnatal development and in the later stages of adulthood. 
Dnmt1 is highly expressed in the embryonic CNS (Goto et al. 1994; Trasler et al. 1996; 
Inano et al. 2000). Dnmt3b is expressed in the ventricular zone (VZ) during a narrow 
period between E10.5 and E13.5, but its levels decrease to undetectable levels in the CNS 
after E15.5 (Feng et al. 2005; Lister et al. 2013a). In contrast, Dnmt3a is expressed in the 
proliferating neural precursors of the VZ and subventricular zone (SVZ) in the embryo. 
However, after birth, Dnmt3a becomes predominantly expressed by postmitotic neurons. 
Its expression in these neurons continues to go up until three weeks of postnatal life, after 
which it declines to low levels in adulthood (Feng et al. 2005; Lister et al. 2013a). Taken 
together, the unique expression pattern of the DNA methyltransferases suggest non-
overlapping roles in the embryonic and postnatal brain.  
 To determine whether the DNA methyltransferases are required for mammalian 
development, several labs have generated global and conditional knockout mice of Dnmt1, 
Dnmt3a and Dnmt3b. Conditional deletion of Dnmt1 using a Emx1-Cre transgene results in 
extensive cell death in the dorsal forebrain (Hutnick et al. 2009). Interestingly, although the 
Dnmt1f/f Emx1-Cre mice are viable and exhibit a normal lifespan, these mice display 
multiple neurobehavioral defects including hyperactivity and impaired fear conditioning 
and learning and memory (Hutnick et al. 2009). While both Dnmt3a+/- and Dnmt3b+/- mice 
appear normal and are fertile, Dnmt3a-/- mice exhibit retarded growth after birth and die at 
approximately three to four weeks of age (Okano et al. 1999) (Fig. 1.8A). On the other hand, 
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Dnmt3b-/- mice are embryonic lethal and exhibit growth impairment and rostral neural 
tube defects (Fig. 1.8B). Generation of Dnmt3a-/- Dnmt3b-/- double knockout mice results in 
a smaller sized embryo that is also embryonic lethal at E11.5 (Okano et al. 1999) (Fig. 1.9). 
To specifically examine the consequence of Dnmt3a loss in the CNS, Nguyen et al. (2007) 
generated a conditional knockout mouse in which Dnmt3a was deleted in the CNS using the 
Nestin-Cre transgene. Dnmt3af/f Nestin-Cre mice were born at the expected Mendelian 
ratio and were healthy at birth, but the males later developed growth retardation, and the 
mutant mice exhibited shortened lifespan. In addition, although there were no major 
structural or anatomical defects in the CNS of the Dnmt3af/f Nestin-Cre mice, these mice 
exhibited various neurobehavioral deficits, including hypoactivity, reduced exploratory 
behavior, reduced grip strength and gait abnormalities (Nguyen et al. 2007).  
In humans, dysregulated expression of the DNA methyltransferases has been 
extensively studied in the context of various cancers (Subramaniam et al. 2014). For 
example, overexpression of Dnmt1 has been observed in prostate cancer and endometrioid 
carcinomas and is also associated with poorer tumor differentiation in gastric cancers. 
Mutations in Dnmt3a are also commonly found in patients with acute myeloid leukemia 
(Ley  et al. 2010; Yan et al. 2011). In addition to the dysregulation of DNA 
methyltransferases in cancers, patients with loss of function mutations in Dnmt1 have been 
found to exhibit hereditary sensory neuropathy with dementia, hearing loss and early 
lethality (Klein et al. 2011). These patients exhibit both central and peripheral nervous 
system degeneration. Sensory neuropathy in these patients leads to loss of sensation in the 
extremities, resulting in infections and thus amputation of their limbs. Mutations in 
Dnmt3a have also been found in patients. Exome sequencing of patients with an 
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overgrowth syndrome, intellectual disability and facial dysmorphism revealed two Dnmt3a 
mutations that interfere with domain-domain interactions and histone binding, which 
result in reduced methyltransferase activity (Tatton-Brown et al. 2014) (Fig. 1.10). 
Collectively, these studies in mice and humans point to the essential role that the 
maintenance and de novo DNA methyltransferases play in the survival of the embryo and 
the proper development of the brain.  
 
The readers 
MeCP2 (methyl-CpG binding protein 2) was initially discovered more than 20 years 
ago by Bird and colleagues in a search for proteins that bound methylated DNA. MeCP2 is 
an X-linked gene whose gene product binds to a symmetrical pair of mCG across the 
genome. More recently, MeCP2 was found to bind to methylated cytosines adjacent to a 
nucleotide other than guanine (CH methylation, discussed below). MeCP2 functions to 
transcriptionally repress genes through its recruitment of and interaction with its 
corepressors including histone deacetylases and Sin3A proteins at the promoter of target 
genes (Nan et al. 1998). MeCP2 binds to methylated cytosines via its methyl-CpG-binding 
domain (MBD) (Nan et al. 1993). The other domain in MeCP2 that is critical for its function 
is the transcription repression domain (TRD), a region in the protein that has been shown 
to bind to Sin3A. Sin3A was previously shown to recruit and bind to histone deacetylases 
HDAC1 and HDAC2 (Hite et al. 2009), which remodel chromatin so that genes are 
transcriptionally repressed. 
MeCP2 is known to be expressed across all tissues; however, it is most highly  
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expressed in the brain, with its expression being five- to ten-fold higher in neurons 
than in other cell types. In fact, studies on the timing and distribution of MeCP2 expression 
revealed that MeCP2 protein expression is highest in the maturing neurons in the CNS. For 
example, the ontogenetically older structures such as the spinal cord and brainstem 
neurons express MeCP2 at an earlier stage before the hippocampus and cerebral cortex, 
which are structures that develop later in the embryo. In addition, deeper layer neurons in 
the cortex begin to express MeCP2 earlier than upper layer neurons, consistent with when 
these neurons are born in the cerebral cortex (Shahbazian et al. 2002a).  
Proper neurodevelopment relies on strict regulation of MeCP2 levels in the brain. 
Mutations in MeCP2 have been shown to cause a variety of syndromes. For instance, 
missense, frameshift and nonsense mutations in MeCP2 lead to the loss of function of 
MeCP2 and were shown to cause Rett syndrome (RTT). RTT is a neurodevelopmental 
disorder first described in 1966 by pediatrician Andreas Rett, who noticed progressive 
dementia, motor loss and stereotypic hand movements in two young girls who had a 
normal developmental course for the first 1 to 1.5 years after birth (Rett 1966). The 
disorder did not receive much attention until 1983 when Swedish neurologist Bengt 
Hagberg and others noted patients with similar features in Europe and published their 
findings in the Annals of Neurology (Hagberg et al. 1983). This disorder almost exclusively 
occurs in females and is one of the most common causes of mental retardation in females. 
RTT is believed to be sporadic in 99% of cases, and the incidence of this disorder is 
approximately 1 in 10,000 live female births. Patients with RTT appear normal at birth and 
undergo a normal course of development for the first 6-18 months after birth, but they  
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progressively fail to meet developmental milestones and exhibit features such as 
microcephaly, scoliosis, seizures, autistic features, gait abnormalities, gradual loss of 
expressive language and hand use, and stereotypic hand wringing movements. The 
spectrum of phenotypes that patients exhibit vary widely from mild mental retardation to 
the classic features of RTT. In addition to the types of mutations seen in the MeCP2 gene, 
one explanation for this diversity in clinical features may be attributed to X-chromosome 
inactivation (XCI). Favorable patterns of XCI or heavily skewed XCI can alleviate the effects 
of the MeCP2 mutation and thus lead to a milder clinical phenotype in patients (Young and 
Zoghbi 2004). Mice lacking MeCP2 or those carrying a truncated allele of MeCP2 undergo 
normal development until 4-6 weeks of age but subsequently develop various 
neurobehavioral abnormalities including seizures, hypoactivity, stereotypies, and early 
death (Chen et al. 2001; Guy et al. 2001; Shahbazian et al. 2002b). Furthermore, in-depth 
characterizations of mice lacking MeCP2 in GABA-releasing neurons demonstrated that 
these mice recapitulate many of the features seen in patients with RTT, including repetitive 
behaviors, increased sociability, and impaired motor coordination (Chao et al. 2010). 
Extensive molecular analyses revealed that these mice exhibited a reduction in presynaptic 
GABA release and inhibitory neurotransmission, leading to hyperexcitability in the brain. 
These findings suggest that a strict balance between excitation and inhibition is necessary, 
the loss of which results in a dysregulation of normal neurodevelopment. 
While RTT is caused by the loss of function of the MeCP2 gene, extra copies of the 
MeCP2 gene in patients can lead to MeCP2 duplication syndrome (MDS), a condition also  
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known as Lubs X-linked mental retardation syndrome (Ramocki et al. 2010; Van 
Esch 2012). MDS is known to occur almost exclusively in males (Van Esch 1993; Villard 
2007) and accounts for 1% of unexplained X-linked intellectual disability in males 
(Lugtenberg et al. 2008). Females with a duplication of MeCP2 are rarely reported and are 
usually asymptomatic, possibly due to highly skewed XCI, in which the X chromosome 
bearing the extra copy of MeCP2 becomes preferentially inactivated (Ramocki et al. 2010). 
However, mild to severe cognitive impairment was previously described in a subset of 
female patients (Grasshoff et al. 2011; Scott Schwoerer et al. 2014). Patients with MDS 
exhibit features such as moderate to severe intellectual disability, autistic features, delayed 
development, seizures and premature death (Van Esch 2012). Several labs have generated 
mouse models that recapitulate the clinical features seen in patients with MDS. Bodda et al. 
generated a transgenic mouse in which MeCP2 was mildly overexpressed (MeCP2WT_EGFP). 
These mice displayed increased aggression and were more sensitive to undergoing 
pentylenetetrazole (PTZ)-induced epileptic seizures (Bodda et al. 2013). Huda Zoghbi’s 
group generated a mouse model in which the human wildtype MeCP2 protein was 
overexpressed at approximately two-fold levels in transgenic mice (MeCP2Tg). These 
MeCP2Tg mice were developmentally normal until 10 weeks of age but developed a 
progressive neurological phenotype, including forepaw clasping, aggression (as 
determined by an increased propensity to bite), and kyphosis. Up until 20 weeks of age, 
MeCP2Tg mice exhibit increased rearing, which is suggestive of reduced anxiety in these 
mice, as well as enhanced cerebellar and hippocampal learning and enhanced synaptic 
plasticity in the hippocampus. After 20 weeks of age, however, these mice underwent clonic 
seizures, had abnormal electroencephalographic traces and exhibited early lethality 
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(Collins et al. 2004). Overexpression of MeCP2 specifically in neurons (Tau-MeCP2) 
recapitulates the features of MDS, including ataxia, impairments in learning and memory, a 
progressive retardation in growth and body weights, and heightened anxiety, along with 
defects in excitatory synapse function. Zilong Qui’s group in China developed a transgenic 
cynomolgus monkey (Macaca fascicularis) overexpressing MeCP2 in the brain. These 
transgenic monkeys displayed autism-like behaviors with increased repetitive circular 
motions, increased anxiety and reduced social interaction with both wildtype monkeys and 
other MeCP2 transgenic monkeys (Liu et al. 2016). Recently, to determine whether the 
phenotypes in the MeCP2Tg mice are reversible, Sztainberg et al. generated a conditional 
MeCP2-overexpressing mouse model to correct MeCP2 levels to wildtype levels and 
showed that the correction rescued many of the behavioral and electrophysiological 
features seen in the MeCP2Tg mice. In addition, the authors used an antisense 
oligonucleotide (ASO) against MeCP2 and successfully corrected the phenotype in the 
MeCP2Tg mice with gradual intracerebroventricular infusion of the ASO (Sztainberg et al. 
2015). These findings reveal the promising therapeutic approach in successfully delivering 
ASOs to patients with MDS and reversing their neurological defects.  
Taken together, the studies in patients with RTT and MDS and animal models that 
recapitulate these disorders suggest that maintaining proper levels of MeCP2, particularly 
in the brain, is essential for normal brain development and maturation, and that too little or 
too much MeCP2 can have devastating neurological consequences.  
 
The erasers 
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Although DNA methylation is a relatively stable epigenetic mark, the erasure of DNA 
methylation has been shown to occur and was also determined to be a stable DNA 
modification instead of a transient intermediate. The methylation of cytosines by the DNA 
methyltransferases generates 5-methylcytosine (5mC), which can further be oxidized by 
ten-eleven translocation (Tet) proteins into 5-hydroxymethylcytosine (5hmC), 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Wu and Zhang 2011) (Fig. 1.11). 
These oxidation products are believed to be intermediates involved in DNA demethylation 
and are thought to contribute to another layer of epigenetic regulation (He et al. 2011; 
Bender and Weber 2013). Although the existence of hmC was noted more than 40 years 
ago (Penn et al. 1972), its significance in CNS neurons has only begun to be explored 
recently. In 2009, Kriaucionis and Heintz revealed the presence of 5hmC in the cerebellar 
Purkinje neurons of the brain (Kriaucionis and Heintz 2009). Examination of the levels of 
5hmC across various stages of development in the cerebellum revealed a progressive 
increase in 5hmC from the early postnatal period to the adult stage (Song et al. 2011). 
Using a highly sensitive LC-MS method to detect the levels of hmC across various tissues in 
mice, Globisch et al. found that, although 5hmC is present across all tissues, the highest 
levels of 5hmC are detected in the brain and the spinal cord (Globisch et al. 2010).  5hmC 
levels were also found to inversely correlate with proliferation, as 5hmC levels were high in 
differentiated cells that exhibited low levels of proliferation (e.g. brain, liver, intestinal villi) 
and were low in actively proliferating cells of the germ centers in the spleen and the 
intestinal crypts (Bachman et al. 2014).  
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The three mammalian Tet proteins, Tet1, Tet2 and Tet3, are dioxygenases that have 
all been shown to catalyze the oxidation of 5mC into 5hmC and its subsequent oxidation 
products. However, the consequence of Tet deficiency in the brain is still unclear. The Tet1 
transcript is expressed in hippocampal neurons, and its transcript levels were found to be 
downregulated by neuronal activity upon KCl-induced cell depolarization in vitro and upon 
flurothyl-induced seizures in vivo (Kaas et al. 2013). Similarly, Tet3 mRNA was also found 
to be responsive to neuronal activity in cortical neurons (Li et al. 2014b), suggesting that 
the activity that helps to shape circuits in the brain leads to increases in hmC levels. To 
determine the consequence of Tet1 deletion in the brain in vivo, Zhang et al. generated Tet1 
knockout mice and found that the mice were viable and fertile and had no growth or 
anatomical abnormalities during the early stages of development. However, the Tet1 
knockout mice displayed reduced neurogenesis in the adult brain and resulted in a smaller 
neural progenitor pool in the dentate gyrus of the hippocampus, which was suggested to 
contribute to their impaired spatial learning and memory.  
Although hmC and the subsequent oxidation products are largely believed to be 
intermediates in DNA demethylation, their exact roles are unknown. Their function in the 
CNS has also been largely unexplored. In fact, the Tet proteins are known to preferentially 
bind to and oxidize CG compared with CH, and most of the hmC in the brain occurs in a CG 
context (Lister et al. 2013b). These findings may thus explain the low levels of hmCH in the 
brain (Hu et al. 2013).  
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1.6  MicroRNAs and DNA methylation: Focus on miR-29 
MicroRNAs are small non-coding RNAs that are evolutionarily conserved. 
MicroRNAs were only very recently discovered (the first microRNA was described in 1993) 
(Lee et al. 1993), but they have gained rapid attention due to their ability to modulate the 
expression of more than half of the mammalian genome (Bartel 2004). They function by 
binding to the 3’UTR of target mRNAs and by preventing either the transcription or 
translation of these mRNAs . MicroRNAs are 18-22 nucleotides in length and can be present 
both in intergenic regions as well as in the introns of genes.  They are first produced in the 
cell as primary microRNA transcripts (or pri-miRNAs), which are cleaved by an enzyme 
known as Drosha into the precursors of microRNAs (pre-miRNAs) (Guo et al. 2010). The 
pre-miRNAs are then exported into the cytoplasm by the protein exportin. The exported 
pre-miRNAs are cleaved by the protein Dicer, giving rise to mature microRNAs. The mature 
miRNAs are then loaded onto a multiprotein complex called RISC (RNA-induced silencing 
complex), eventually allowing the microRNA to regulate mRNA levels either by the 
degradation or translational repression of the mRNA. 
Recent work has revealed that microRNAs could play a role in DNA methylation. For 
example, miR-148 has been shown to target Dnmt3b and Dnmt1 in HeLa cells and in 
cholangiocarcinoma cell lines. miR-126 and miR-152 were also previously shown to target 
the 3’UTR of Dnmt1. Several of these microRNAs have also been shown to be dysregulated 
in various human cancers. Recently, the miR-29 family members were shown to directly 
target Dnmt3a and Dnmt3b, and overexpression of this microRNA family in lung cancer cell 
lines and acute myeloid leukemia cell lines led to reduced global DNA methylation (Denis et 
al. 2011).  
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The miR-29 family consists of three family members, miR-29a, miR-29b and miR-
29c (Kriegel et al. 2012). These three members are expressed from two distinct loci as miR-
29ab1 and miR-29cb2. Many of the targets as well as the target sites are broadly conserved 
across different species. According to targetscan.org, miR-29b has at least 2777 transcript 
sites.  Due to its ability to modulate multiple genes and pathways, this microRNA has been 
widely studied in a variety of contexts including cancer, neurodegeneration, diabetes, and 
aging (Hebert et al. 2008; Ugalde et al. 2011; Xu et al. 2015).  Interestingly, miR-29 has the 
ability to target two genes that have opposite functions in the same pathway. For example, 
in certain cancer cell lines, miR-29 is known to target Mcl-1, an anti-apoptotic gene (Mott et 
al. 2007), thus making this microRNA an attractive molecule for tumor therapy. In contrast, 
in peripheral neurons, miR-29 is known to target pro-apoptotic BH3-only proteins, thereby 
preventing cell death (Kole et al. 2011). These findings underscore the contextual and 
spatial differences of miR-29 function in different cell types. 
The role of miR-29 is especially important in the nervous system, as the neurons in 
the brain engage miR-29 to inhibit the apoptotic pathway. Inhibition of apoptosis is crucial 
in neurons, which are postmitotic and cannot afford to remain susceptible to apoptosis 
after the nervous system has developed.  Upon screening for microRNAs that were induced 
upon neuronal maturation, Kole et al. discovered that miR-29 was markedly induced in 
mature neurons and that this microRNA promoted survival by regulating the expression of 
multiple pro-apoptotic BH3-only proteins (Kole et al. 2011). However, the role of miR-29 in 
the context of DNA methylation and brain maturation in the CNS is still poorly understood 
and remains to be investigated. 
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1.7 Non-canonical CH methylation 
 Although the role of the DNA methyltransferases and MeCP2 in CG methylation had 
been known for some time, the recently discovery of non-canonical DNA methylation has 
paved the path for understanding the molecular mechanisms behind the development and 
maturation of the brain under both physiological conditions and in the context of 
neurodevelopmental disorders. While canonical CG methylation (mCG) involves the 
methylation of a cytosine that is adjacent to a guanine nucleotide, non-canonical cytosine 
methylation results in the methylation of a cytosine that is adjacent to a non-guanine 
nucleotide (referred to as mCH, where H = adenine (A), cytosine (C), or thymine (T)) (Xie et 
al. 2012; Lister et al. 2013b; Shin et al. 2014a; He and Ecker 2015; Kinde et al. 2015), with 
mCA being the most predominantly methylated residue in mCH methylation.  
 
Non-CH methylation in pluripotent stem cells 
While mCH methylation has been found to occur in various tissue types throughout 
the human body (Schultz et al. 2015), the highest levels of mCH methylation have been 
found in human embryonic stem cells (ESCs) (Ramsahoye et al. 2000; Laurent et al. 2010; 
Lister et al. 2013a) and in the mammalian brain (Xie et al. 2012; Zeng et al. 2012; Lister et 
al. 2013a). The presence of non-CG methylation in ESCs was first described in 2000 by 
Rudolf Jaenisch’s lab in which they used bisulfite sequencing methods to show that ESCs 
have higher levels of non-CG methylation compared to various somatic tissues including 
the liver, kidney, spleen and lung. These sites of non-CG methylation were shown to occur 
primarily at CA and CT sites. Expression of Dnmt3a in Drosophila led to the methylation of 
both CG and non-CG sites, suggesting that non-CG methylation in ESCs was mediated by 
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Dnmt3a (Ramsahoye et al. 2000). Lister et al. found that, compared to the IMR90 fetal lung 
fibroblasts in which 0.02% of the genome was methylated in the non-CG context, the DNA 
of male-derived human ESCs (H1) was found to have high levels of mCH, with nearly a 
quarter of all methylated sites being non-CG methylated (Lister et al. 2009). In addition to 
ESCs, induced pluripotent stem cells (iPSCs) are also known to display high levels of mCH. 
Interestingly, Lister et al. found that iPSCs derived from the IMR90 cells underwent a 
restoration of non-CG methylation, suggesting that non-CG methylation in the epigenome is 
reconfigured during the process of differentiation and de-differentiation (Lister et al. 
2009). 
  
Non-CH methylation in the maturing brain 
 Non-CG methylation occurs at very low levels and is virtually undetectable in the 
embryonic and early postnatal frontal cortex, but its levels gradually increase between 
birth and the adolescent period and plateaus as the brain undergoes maturation (Fig. 1.12). 
Similar patterns of mCH accumulation have been found in the dentate gyrus of the 
hippocampus in mice (Guo et al. 2014). Consistent with this accumulation of mCH during 
brain maturation, the levels of Dnmt3a peak at approximately ten days after birth in the 
mouse frontal cortex and are markedly reduced by postnatal day 20 (Lister et al. 2013b). In 
fact, this period during which mCH accumulates coincides with the stage of synaptogenesis 
and synaptic refinement (Lister et al. 2013a).  
 In addition to recognizing and binding to mCG across the mammalian genome, 
MeCP2 was recently found to bind to mCH sites and repress gene expression (Guo et al. 
2014; Chen et al. 2015; Gabel et al. 2015). Gabel et al. found that MeCP2 normally binds to 
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mCA sites within long genes, many of which are associated with neuronal function, and 
represses their transcription. In both MeCP2 mutant mouse models and postmortem 
human RTT brains a length-dependent increase in gene expression was observed. 
Furthermore, Chen et al. found that genes that acquire non-CG methyl marks after birth 
tend to become dysregulated in mouse models of RTT, suggesting that regulation of mCH 
by MeCP2 is critical in the postnatal brain. These findings suggest that one of the 
mechanisms underlying the pathogenesis in RTT could be the dysregulated expression of 
long genes in the developing and maturing brain. 
 
These observations and the recent interest in non-CG methylation in the brain raise 
several fascinating questions. What controls the expression of the DNA methyltransferases 
and thereby regulates noncanonical DNA methylation in the maturing brain? Are there 
microRNAs that govern the critical period during which non-canonical DNA methylation 
occurs? What are the anatomical and behavioral consequences of upregulating the 
expression of DNA methyltransferases in the maturing brain? Several of these points are 
addressed in this thesis and remain under intense investigation as studies on the role of 
non-CG methylation in the brain continue to grow.   
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1.8 Figures and Legends 
 
Figure 1.1: Apoptosis is essential for proper embryonic development.  
 
Gross morphology of caspase-9 heterozygous (A) and homozygous (B) embryos isolated at 
embryonic day 16.5 (E16.5). By this time point, a severe malformation (excencephaly) of 
the brain in the caspase-9 homozygous knockout mice can be seen.   
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Figure 1.1 
 
 
 
 
Figure adapted from Kuida et al., Cell (1998) 
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Figure 1.2: The intrinsic and extrinsic pathways of apoptosis. 
 
(A) The intrinsic pathway of apoptosis. Following apoptotic stimuli, the pro-apoptotic 
proteins Bax and Bak are activated and lead to the release of cytochrome c from the 
mitochondria into the cytosol. Cytochrome c then binds to Apaf-1, inducing the formation 
of the apoptosome that activates downstream caspases to induce the death of the cell. (B) 
The extrinsic pathway of apoptosis. After a ligand binds to the death receptor, downstream 
adaptor molecules are recruited and results in the dimerization and activation of caspase-8.  
Caspase-8 can either directly activate caspase-3 and caspase-7 without the involvement of 
mitochondria, or it can activate and cleave Bid into tBid, which  engages Bax and Bak to 
mediate the mitochondrial-dependent pathway of apoptosis.  
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Figure 1.2 
 
 
 
From Tait and Green, Nature Reviews Molecular Biology (2010) 
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Figure 1.3: Members of the Bcl-2 family of proteins. 
 
The Bcl-2 family of proteins is composed of pro-apoptotic and anti-apoptotic members. 
These proteins are classified according to the number of Bcl-2 homology (BH) domains 
present within the proteins.  The anti-apoptotic family members, which include Bcl-2, Bcl-
xL, Bcl-w, A1, and Mcl-1, contain a total of four BH domains (BH1-BH4).  The pro-apoptotic 
proteins Bax, Bak and Bok contain three BH domains (BH1-BH3), while the other group of 
pro-apoptotic proteins, the BH3-only family members, contains only the BH3 domain. 
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Figure 1.3 
 
 
 
From Tait and Green, Nature Reviews Molecular Biology (2010) 
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Figure 1.4: Formation of the mammalian apoptosome complex. 
 
Normally, in healthy cells that have not released cyt c from the mitochondria, Apaf-1 exists 
in a monomeric state in which the WD40 repeats fold back to prevent dATP and caspase-9 
from binding to the protein domains in Apaf-1.  Upon mitochondrial release of cyt c, cyt c 
binds to the WD40 repeats of Apaf-1, exposing the ATPase domain. Apaf-1 subsequently 
undergoes a conformational change that allows the binding of dATP and caspase-9, 
resulting in the formation of the apoptosome.  
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Figure 1.4 
 
 
Adapted from Ow et al., Nature Reviews Molecular Biology (2008) 
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Figure 1.5: Programmed cell death in the peripheral and central nervous systems. 
 
While the apoptotic pathway in the peripheral nervous system is governed by the 
neurotrophic theory (i.e. the number of neurons innervating the tissue must match the size 
of the target tissue), the developing neurons in the CNS do not appear to rely on a single 
trophic factor for survival, and the mechanisms underlying apoptosis in the CNS are still 
poorly understood.  
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Figure 1.5 
 
 
 
From Dekkers and Barde, Science (2013) 
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Figure 1.6: Mechanisms by which DNA methylation induces transcriptional 
repression. 
 
(A) The presence of DNA methylation in the DNA binding sequences of the promoter region 
prevents the binding of transcription factors and thus mediates gene silencing. (B) 
Methylated DNA is recognized by the methyl-CpG-binding proteins (MBPs), which function 
to recruit corepressor proteins to mediate gene silencing.  
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Figure 1.6 
 
 
 
Adapted from Klose and Bird, Trends in Biochemical Sciences (2006) 
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Figure 1.7: Bisulfite genomic sequencing. 
 
 
After genomic DNA is isolated from cells or tissues, the DNA is treated with sodium 
bisulfite. Sodium bisulfite treatment converts non-methylated cytosines into uracils, while 
methylated cytosines are protected from sodium bisulfite conversion and are still read as 
cytosines. The DNA is then prepared for sequencing.  
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Figure 1.7 
 
 
 
 
From Li and Tollefsbol, Methods in Molecular Biology (2011) 
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Figure 1.8: Phenotypes of the Dnmt3a and Dnmt3b knockout mice. 
 
(A) An image of wildtype and Dnmt3a-deficient mice at postnatal day 18. Although 
Dnmt3a-/- mice are born at the expected Mendelian ratio and appear normal at birth, they 
undergo growth retardation and die at approximately four weeks of age. (B) An image of 
wildtype and Dnmt3b-deficient embryos at embryonic day 11.5. The image shows an 
enlarged head region in the Dnmt3b-/- mice indicative of a rostral neural tube defect.  
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Figure 1.8 
 
 
 
 
 
 
Adapted from Okano et al., Cell (1999) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 41 
 
Figure 1.9: Mice deficient in both Dnmt3a and Dnmt3b are embryonic lethal. 
 
(A) Wildtype and (B) Dnmt3a/Dnmt3b double homozygous embryos at embryonic day 9.5. 
These mice deficient in both Dnmt3a and Dnmt3b have smaller body size, fail to form 
somites and die before embryonic day 11.5.  
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Figure 1.9 
 
 
 
 
 
Adapted from Okano et al., Cell (1999) 
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Figure 1.10: Facial dysmorphic features in patients with DNMT3A overgrowth 
syndrome. 
 
(A-H) Photographs of patients with DNMT3A overgrowth syndrome, which is 
characterized by greater height, intellectual disability and facial dysmorphism.  
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Figure 1.10 
 
 
 
 
 
From Tatton-Brown et al., Nature Genetics (1999) 
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Figure 1.11: Cytosine methylation and hydroxymethylation are mediated by the DNA 
methyltransferases and ten-eleven translocation proteins, respectively. 
 
While the five-position carbon on cytosines in the mammalian genome are methylated by 
the DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b, the methylcytosines can be 
further oxidized to hydroxymethylcytosines by the Tet enzymes, Tet1-3. 
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Figure 1.11 
 
 
 
 
 
 
 
From Kinde et al., Proceedings of the National Academy of Sciences (2015) 
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Figure 1.12: Levels of mCG and mCH in the mouse and human frontal cortex across 
age. 
 
MethylC-seq analysis on mouse and human frontal cortex reveal the pattern of mCG and 
mCH levels across age. mCH levels accumulate during the early postnatal stages, and this 
increase coincides with the period of synaptogenesis and continues to increase during the 
period of synaptic pruning in the postnatal brain.  
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Figure 1.12 
 
 
 
 
Adapted from Lister et al., Science (2013)  
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CHAPTER TWO: BCL-XL IS ESSENTIAL FOR THE SURVIVAL AND FUNCTION OF 
DIFFERENTIATED NEURONS IN THE CORTEX THAT CONTROL COMPLEX BEHAVIORS 
 
2.1 Overview 
Apoptosis plays an essential role during brain development, yet the precise 
mechanism by which this pathway is regulated in the brain remains unknown.  In 
particular, mammalian cells are known to express multiple anti-apoptotic Bcl-2 family 
proteins.  However, the cells of the developing brain could also exist in a primed state 
where the loss of a single anti-apoptotic Bcl-2 family protein is sufficient to trigger 
apoptosis.  Here, we examined the critical role of Bcl-xL, an anti-apoptotic protein, during 
brain development. Using conditional knockout mice in which Bcl-xL is deleted in neural 
progenitor cells (Bcl-xLEmx1-Cre), we show that the loss of Bcl-xL is not sufficient to trigger 
apoptosis in these proliferating progenitors.  In contrast, specific populations of postmitotic 
neurons derived from these progenitors, including upper layer cortical neurons and the 
CA1-CA3 regions of the hippocampus, were acutely dependent on Bcl-xL.  Consistent with 
this finding, deletion of Bcl-xL selectively in the postmitotic neurons in the brain (Bcl-xLNex-
Cre) also resulted in similar patterns of apoptosis.  This Bcl-xL deficiency-induced neuronal 
death was a consequence of activation of the apoptotic pathway, as the cell death was 
rescued with co-deletion of the pro-apoptotic proteins Bax and Bak.  Importantly, the loss 
of these Bcl-xL-dependent neurons led to severe neurobehavioral abnormalities including 
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deficits in motor learning, hyperactivity, and increased risk-taking and self-injurious 
behaviors.  Together, our results identify a population of neurons in the developing brain 
that are acutely dependent on Bcl-xL during the peak period of synaptic connectivity that 
are important for the establishment of higher order complex behaviors. 
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2.2 Introduction 
Regulation of apoptosis is critical for proper embryonic and early postnatal brain 
development (Raff et al. 1993).  The apoptotic pathway in the peripheral nervous system 
(PNS) is well known to be regulated by target-derived trophic factors that maintain the 
survival of neurons that are properly innervated at their distal targets (Oppenheim 1991).  
In contrast, while neurons in the central nervous system (CNS) are known to undergo 
apoptosis during development (Kuida et al. 1996; Cecconi et al. 1998; Hakem et al. 1998; 
Yoshida et al. 1998), exactly how apoptosis is regulated in the developing CNS remains 
unclear.  For example, in contrast to PNS neurons, neurons in the developing CNS do not 
rely on a single trophic factor for their survival (Dekkers et al. 2013).   However, increasing 
evidence indicates that CNS neurons rely more on neuronal activity and proper wiring of 
synaptic connections to maintain their survival (Dekkers and Barde 2013). 
The key regulators of apoptosis are the Bcl-2 family proteins, which contain 
multiple pro-apoptotic (e.g. Bax, Bak) and anti-apoptotic (e.g. Bcl-2, Bcl-xL, Mcl-1, Bcl-w) 
proteins (Youle and Strasser 2008; Chipuk et al. 2010).   While these pro- or anti-apoptotic 
proteins are generally thought to have redundant functions, the emerging data points to a 
level of functional specificity for individual proteins that had not been previously 
appreciated.  For example, deletion of Bax alone is sufficient to inhibit apoptosis in 
postmitotic neurons (Deckwerth et al. 1996; Besirli et al. 2003).  In addition, while loss of 
Mcl-1 results in peri-implantation embryonic lethality (Rinkenberger et al. 2000), Bcl-xL-/- 
global knockouts survive longer but are still embryonic lethal, with most knockouts dying 
at gestational day 13.5 (E13.5) (Motoyama et al. 1995).  The cause of death in Bcl-xL-
deficient mice is postulated to be the extensive cell death that occurs in the liver 
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hematopoietic cells, subsequently leading to anemia in these animals; however, another 
major organ system affected by loss of Bcl-xL is the brain (Motoyama et al. 1995; Roth et al. 
1996).   
Bcl-xL is known to be expressed in both the embryonic and adult brain (Gonzalez-
Garcia et al. 1994; Gonzalez-Garcia et al. 1995).  Telencephalic neurons deficient in Bcl-xL 
are more sensitive to apoptosis both in vivo and in vitro (Motoyama et al. 1995; Roth et al. 
1996).  Moreover, in recent years, there has been increasing attention on the role of Bcl-xL 
in regulating processes beyond neuronal apoptosis, including neurite outgrowth (Kretz et 
al. 2004; Park et al. 2015), synaptic plasticity (Jonas et al. 2003; Li et al. 2008; Li et al. 2013) 
and mitochondrial bioenergetics (Vander Heiden et al. 2001; Chen et al. 2011).  Although 
there has been focus on both the apoptotic and non-apoptotic roles of Bcl-xL in the nervous 
system, a systematic examination of the consequence of Bcl-xL deficiency in the brain has 
not been conducted to date. 
Here, we generated conditional knockout mice in which Bcl-xL is specifically deleted 
in the neural progenitor cells (NPCs) of the telencephalon and in the postmitotic cells of the 
brain.  We show that, while loss of Bcl-xL appears to be dispensable for the survival of 
NPCs, specific populations of postmitotic neurons in the brain critically rely on Bcl-xL for 
their survival and function. The brains of Bcl-xL-deficient mice displayed severe 
microcephaly as a result of increased apoptotic cell death in the neurons of the cortex and 
hippocampus during the early postnatal stages, a phenomenon that is rescued with 
deletion of Bax and Bak. In vivo imaging for visually evoked neural activity in mice deleted 
for Bcl-xL revealed an abnormally small retinotopic map in the visual cortex that, 
surprisingly, remained topographically intact and functional. Importantly, Bcl-xL deficiency 
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led to severe consequences in the animal, including deficits in motor learning, self-injurious 
behavior, overt hyperactivity, and increased risk-taking behavior.  Together, these results 
point to the critical role of Bcl-xL in the survival of specific postmitotic neurons in the 
developing mammalian brain, the loss of which results in neurobehavioral deficits. 
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2.3 Results and Discussion 
Bcl-xL deletion leads to cell death of newly differentiated neurons 
Mice globally deleted for Bcl-xL are embryonic lethal at E13.5 (Motoyama et al. 
1995).  While Bcl-xL is known to regulate apoptosis in neurons, its essential role in the 
survival of hematopoietic cells precluded studies that could identify the precise function of 
Bcl-xL in the nervous system.  To critically examine the role of Bcl-xL in the developing 
brain, we generated conditional knockouts by crossing mice floxed for Bcl-xL with Emx1-
Cre mice (Bcl-xLloxP/loxP; Emx1-Cre, hereafter referred to as Bcl-xLEmx1-Cre).  To confirm that 
Emx1-Cre induces recombination in the NPCs of the dorsal telencephalon (Gorski et al. 
2002), we also generated Emx1-Cre; rosa26reporter-tdTomato mice.  As expected, there is 
robust expression of tdTomato in the dorsal telencephalon at E12.5 (Fig. 2.1A).  Our results 
show that Bcl-xL expression is lost throughout all layers of the cortex in the Bcl-xLEmx1-Cre 
mice (Fig. 2.1B).  A few neurons, including excitatory projection neurons and interneurons, 
continue to exhibit Bcl-xL immunoreactivity, as Emx1-Cre is known to induce 
recombination at an efficiency of ~88% in the cortex and does not induce recombination in 
interneurons (Gorski et al. 2002) (Fig. 2.1B).   
In contrast to mice globally deleted for Bcl-xL, Bcl-xLEmx1-Cre mice were born at the 
expected Mendelian ratio and appeared normal at postnatal day 1 (P1) (Fig. 2.1C). At P1, 
the brains of Bcl-xLEmx1-Cre mice also appeared similar to those of wildtype mice, and there 
was no difference in the brain weights between the two genotypes (Fig. 2.1D, E). By P25, 
however, although Bcl-xLEmx1-Cre mice remained grossly normal, examination of their brains 
revealed profound microcephaly (Fig. 2.1F-H).  From P1 to P30, Bcl-xLEmx1-Cre mice also 
exhibited a significant reduction in the cortical thickness, and the number of NeuN-positive 
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cells throughout the cortex at P30 was markedly reduced in the Bcl-xLEmx1-Cre mice (Fig. 
2.2A-G).  
The fact that the deletion of Bcl-xL in the developing brain did not result in 
embryonic lethality prompted us to examine Bcl-xL expression in the developing brain. 
Contrary to our expectation that Bcl-xL is expressed throughout the brain, we found that 
the expression of Bcl-xL was significantly higher in the non-proliferating cells of the cortex 
compared to the proliferating progenitors in the subventricular zone (Fig. 2.3A-C). To 
determine whether the microcephaly observed in Bcl-xLEmx1-Cre mice postnatally was due to 
increased apoptosis, we probed the brains for cleaved caspase-3 at multiple time points 
(E16, P1). Consistent with the expression patterns of Bcl-xL throughout the brain, cell 
death in the Bcl-xL-deficient embryonic brain occurred primarily in the NeuN-positive 
differentiated neurons while the proliferating (PCNA-positive) progenitors were largely 
spared (Fig. 2.3D-H).  Even more striking, we found that deletion of Bcl-xL induces cell 
death and formation of pyknotic nuclei predominantly at P1 in the cortex of the postnatal 
brain (Fig. 2.4A-D).  Analysis of the hippocampus also showed extensive cell death in the 
CA1-CA3 regions of Bcl-xLEmx1-Cre mice at P1 (Fig. 2.4E, F).  Thus, consistent with its pattern 
of expression, deletion of Bcl-xL selectively affects the postmitotic neurons rather than 
their proliferating progenitors. 
 
Bcl-xL deficiency induces cell death predominantly in upper layer cortical neurons 
and results in a significantly smaller but functional visual cortex 
As the majority of cells that are undergoing apoptosis in Bcl-xLEmx1-Cre mice at P1 are 
located in the upper regions of the cortex, we investigated the specific neuronal layers that 
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are affected most by Bcl-xL deficiency. By P30, the Bcl-xLEmx1-Cre mice had a significant 
reduction in the number of Cux1+ cells in layers II/III and Brn1+ cells in layers II-IV of the 
cortex (Fig. 2.4G-J). While deeper layer Tbr1+ neurons also underwent cell death in Bcl-
xLEmx1-Cre mice (Fig. 2.4K, L), cell death was more prominent in the upper layer cortical 
neurons. 
To examine the physiological relevance of loss of Bcl-xL in the brain, we focused on 
the primary visual cortex (V1) as a marker for structural and functional organization of the 
cortex (Fig. 2.5A). Surprisingly, despite the significant reduction in layers II-IV of the cortex, 
in vivo imaging of visual responses to a white bar moving either in a horizontal or vertical 
direction revealed a functional and retinotopically organized visual cortex in Bcl-xLEmx1-Cre 
mice (Fig. 2.5B). Further tests using a vertical grating patch found that, although the 
neurons appeared to be wired in a topographically correct manner, the size of the visual 
cortex as measured by the whole V1 area as well as the area representing a 50-degree 
diameter portion of visual space were both significantly smaller in Bcl-xLEmx1-Cre mice 
compared to their wildtype littermates (Fig. 2.5B-D). In fact, as a consequence of the 
reduced size of the visual cortex, the underlying superior colliculus was fully exposed (Fig. 
2.5A).  Thus, we were able to image the retinotopic organization of the superior colliculus 
within the same field-of-view that contained the visual cortex in the Bcl-xLEmx1-Cre mice (Fig. 
2.5B). Together, these results highlight the importance of Bcl-xL in maintaining the survival 
of upper layer neurons, the loss of which led to markedly smaller, yet functional, areas of 
cortical retinotopy. 
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Neuronal death induced by Bcl-xL deficiency is rescued with co-deletion of Bax and 
Bak 
The key effectors of apoptosis are the pro-apoptotic proteins Bax and Bak, which 
can be activated either directly or indirectly by the loss of their binding to the anti-
apoptotic proteins such as Bcl-xL (Cheng et al. 2001; Kim et al. 2006; Westphal et al. 2014).  
Thus, we examined whether the cell death caused by Bcl-xL deficiency is mediated via a 
Bax- and Bak-dependent apoptotic pathway.  To test this, we crossed Bcl-xLEmx1-Cre mice 
with BaxloxP/loxP; Bak-/- mice to generate BaxloxP/loxP; Bcl-xLloxP/loxP; Emx1-Cre; Bak-/- triple 
knockout mice (triple knockouts hereafter referred to as BBB TKO).  First we confirmed 
that Bcl-xL and Bax underwent recombination in these mice (Fig. 2.6A, B).  Bak, which is 
known to be minimally expressed in postmitotic neurons in the brain (Krajewski et al. 
1996),  is globally deleted in the BBB TKO mice (Fig. 2.6C).  BBB TKO knockouts were born 
at the expected Mendelian ratio and appeared normal at birth (data not shown).  More 
importantly, the apoptotic cell death observed in Bcl-xLEmx1-Cre mice was completely 
rescued in P1 BBB TKO mice (Fig. 2.6D, E).  As a result, the cortical thickness and neuronal 
numbers at P30 were completely restored in these triple knockout mice (Fig. 2.6F-J). 
Together, these findings show that the neuronal death observed in the brains of Bcl-xLEmx1-
Cre mice can be rescued with deletion of Bax and Bak. 
 
Deletion of Bcl-xL in postmitotic neurons leads to selective neuronal death in the 
upper layers of the cortex 
Our results show that inducing deletion of Bcl-xL in the NPCs of the dorsal 
telencephalon leads to the death of mainly postmitotic neurons in the early postnatal 
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animal. To specifically investigate the role of Bcl-xL deletion in postmitotic neurons 
throughout the brain, we utilized the Nex-Cre mouse model. Nex-Cre directs recombination 
in the postmitotic neurons at embryonic day E13.5 and spares recombination in neuronal 
progenitors (Goebbels et al. 2006). Bcl-xLloxP/loxP; Nex-Cre mice (Bcl-xLNex-Cre), similar to 
Bcl-xLEmx1-Cre mice, were born at the expected Mendelian ratio. Interestingly, Bcl-xLNex-Cre 
mice displayed smaller body weights at P30 (Fig. 2.7A, B).  The brains of Bcl-xLNex-Cre mice 
were also smaller compared to their wildtype littermate controls (Fig. 2.7C, D).  
Importantly, deletion of Bcl-xL in postmitotic neurons in Bcl-xLNex-Cre mice still resulted in a 
cell death phenotype in the brain that was similar to what was observed in the Bcl-xLEmx1-
Cre mice, with significantly increased cleaved caspase-3 staining in the upper cortical layers 
at P1 (Fig. 2.7E, F).  Taken together, our results from both the Bcl-xLEmx1-Cre and Bcl-xLNex-Cre 
mice show that the loss of Bcl-xL does not cause widespread apoptosis in the developing 
brain but instead results in the loss of postmitotic neurons in the upper regions of the 
cortex during the early postnatal stages. 
 
Loss of Bcl-xL-dependent neurons results in deficits in motor learning, hyperactivity, 
and increased risk-taking and self-injurious behaviors 
To determine the functional consequence of Bcl-xL deletion in postmitotic neurons, 
we conducted neurobehavioral assessments of wildtype and Bcl-xLNex-Cre mice starting at 
P30. A three-minute tail suspension test revealed that, while wildtype mice exhibited the 
characteristic flailing of their hindlimbs, Bcl-xLNex-Cre mice displayed hindlimb clasping, an 
indicator of generalized neurological dysfunction (Fig. 2.8A, B).  The Bcl-xLNex-Cre mice also 
displayed self-injurious behavior.  Persistent skin lesions in their hindlimbs, chest, neck, 
and other areas began to appear approximately one month after birth and were observed 
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in approximately 50% of these mice (Fig. 2.8C). These lesions were not a result of fighting 
with cage mates, as Bcl-xLNex-Cre mice housed alone also developed these lesions. Analysis of 
grooming behavior revealed that male Bcl-xLNex-Cre mice spent significantly more time 
grooming compared to wildtype controls (Fig. 2.8D). Male Bcl-xLNex-Cre mice also displayed 
an altered sensation to pain, as they were significantly more insensitive to noxious heat 
stimuli on the Hargreaves test (Fig. 2.8E).  
In a multi-test behavioral regimen, both male and female Bcl-xLNex-Cre mice displayed 
increased locomotor activity in the open field test without changes in rearing movements 
or time spent in the center region (Fig. 2.9A-C).  Interestingly, male Bcl-xLNex-Cre mice also 
displayed significantly increased risk-taking behavior as they spent more time in the open 
arms of the elevated plus maze, suggesting a loss of typical cautionary avoidance of the 
open areas (Fig. 2.9D, E). The total number of entries in the elevated plus maze was not 
altered in the knockout mice, indicating that the increased risk-taking behavior in the male 
Bcl-xLNex-Cre mice could not be attributed to general hyperactivity during the test (Fig. 2.9F).   
In contrast to the intact ability for locomotion and rearing movements, the Bcl-xLNex-
Cre knockout mice had profound deficits in motor coordination on an accelerating rotarod.  
The Bcl-xLNex-Cre mice failed to show improvement across repeated trials, indicating 
impaired motor learning in the rotarod test (Fig. 2.9G).  A subset of Bcl-xL-deficient mice 
without skin lesions (8/16) was further evaluated in the Morris water maze task to 
determine the ability of mice to locate a visible escape platform.   While all of the wildtype 
mice demonstrated proficient learning in the visible platform test, Bcl-xLNex-Cre knockout 
mice had an overt impairment in reaching the escape platform, with only two Bcl-xLNex-Cre 
mice meeting the 15-second criterion for learning across three days of testing (Fig. 2.9H, I).  
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Taken together, these results show that Bcl-xL plays a critical role in postmitotic neuronal 
survival and that the Bcl-xL-dependent neurons control a variety of complex behaviors, the 
loss of which results in severe neurobehavioral abnormalities.  
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2.4 Materials and Methods 
Mice. Bcl-xLloxP/loxP mice were generously provided by Dr. You-Wen He (Duke University). 
To induce conditional deletion of Bcl-xL, Bcl-xLloxP/loxP mice were crossed with two different 
Cre lines, Emx1-Cre and Nex-Cre.  Emx1-Cre and tdTomato mice were a kind gift from Dr. 
William Snider (UNC-Chapel Hill) and Dr. Timothy Gershon, respectively (UNC-Chapel Hill).  
All other mice were obtained from Jackson Laboratory. Mice were maintained in a 12 hr 
light, 12 hr dark cycle (lights on at 7AM, lights off at 7 PM). All animal handling and 
protocols were carried out in accordance with established practices as described in the 
National Institutes of Health Guide for Care and Use of Laboratory Animals and as 
approved by the Animal Care and Use Committee at UNC-Chapel Hill. 
 
Surgeries 
For intrinsic signal optical imaging, craniotomy was performed on a total of 6 mice at age 
P29 – 34 (n = 3 wildtype, n = 3 Bcl-xLEmx1-Cre mice). Mice were anesthetized with isoflurane 
(5% for induction, 1-2% for surgery, 0.5% for imaging) augmented with chlorprothixene 
(2.5mg/kg, i.p.). Skull overlaying right visual cortex was exposed, and a custom head-fixing 
imaging chamber with a 5-mm diameter opening was mounted and secured with 
cyanoacrylate glue (Oasis Medical) and dental acrylic (Lang Dental). A 4-mm diameter 
craniotomy was made within the chamber to expose the visual cortex for imaging. The 
imaging chamber was then filled with a saline solution containing (in mM) 150 NaCl, 2.5 
KCl, 10 HEPES, 2 CaCl2, and 1MgCl2. Physically-activated heat packs (SpaceGel, Braintree 
Scientific) and a feedback-controlled electric heat pad system (custom-built; 37°C) were 
used for maintaining body temperature during surgery and imaging, respectively.  
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Intrinsic signal optical imaging 
Custom instrumentation adapted from previous reports (Kalatsky and Stryker 2003; Smith 
and Trachtenberg 2007) was used. Briefly, two F-mount lenses were used to form a tandem 
lens macroscope (respective focal lengths of 135 and 50mm; Nikon) which was connected 
to a Dalsa 1M30 CCD camera (Teledyne DALSA), providing a 4.6mm x 4.6mm field of view. 
The pial vasculature illuminated (Asahi Spectra low noise halogen source) with green light 
(550 ± 50nm, Edmund Optics) and imaged through a green emission filter (560 ± 5nm) 
served as a landmark for depth. From the vasculature, the imaging was focused 600 µm 
deep into the neocortex where hemodynamic intrinsic signals were imaged with red light 
(700 ± 38nm, Chroma). Reflected light was then captured through a second red filter (700 
± 5nm, Edmund Optics) at 30 frames/s with custom image acquisition software (code 
kindly provided by D. Ferster, Northwestern University; with adaptations by J. Stirman, 
University of North Carolina). Fourier analysis was performed on each pixel column to 
measure the magnitude and phase of stimulus-evoked signals at the frequency of the 
periodic visual stimuli (0.125Hz). Area and vertical and horizontal diameters of the entire 
V1 and a portion of V1 representing 50-degree visual space were measured using ImageJ 
software (Schindelin et al. 2012).   
 
Visual stimuli 
Head-fixed mice were positioned 20cm from an LCD monitor (60cm x 34cm) that was tilted 
17.5° from vertical towards the mouse. The nose of the animal was pointed to the right 
edge of the monitor such that the stimulus covered 110° by 75° of visual space and was 
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viewed by the contralateral eye. A 3° thick drifting white bar sweeping across the monitor 
once every 8 seconds on a black background (horizontal or vertical) was used for 
retinotopic mapping, and a vertical grating patch (50° diameter displayed at the center of 
the monitor, 2 cycles/s, 0.04 cycle/°) drifting for the last two seconds of an eight-second 
period was used to measure basic cortical representation of a 50-degree visual space. The 
periodic motion cycle for both of these stimuli was at 0.125Hz and repeated 50 cycles. The 
stimulus movies were produced and presented using MATLAB (Pelli 1997) and the 
Psychophysics Toolbox (Brainard 1997) and were corrected for three dimensional 
distortion due to the flatness of the monitor using a custom MATLAB code (code is 
available online, http://labrigger.com/blog/2012/03/06/mouse-visual-stim/). 
 
Behavioral regimen 
Subjects were 16 Bcl-xLNex-Cre (10 males and 6 females) and 19 wildtype controls (10 males 
and 9 females).  Testing began when mice were approximately 6-7 weeks of age.  For each 
procedure, measures were taken by an observer blind to mouse genotype.  Mice were 
tested in the following assays, with one or two tests per week:  elevated plus maze, open 
field, rotarod, and Morris water maze. 
 
Elevated plus maze.  This test was used to assess anxiety–like behavior, based on a 
natural tendency of mice to actively explore a new environment, versus a fear of being in an 
open area.  Mice were given one 5-min trial on the plus maze, which had two walled arms 
(the closed arms, 20 cm in height) and two open arms.  The maze was elevated 50 cm from 
the floor, and the arms were 30 cm long.  Mice were placed on the center section (8 cm x 8 
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cm), and allowed to freely explore the maze.  Measures were taken of percent time spent in 
the open arms and percent entries into the open arms.  Total number of entries was used as 
an index for activity during the test. 
 
Open field test.  Exploratory activity in a novel environment was assessed by a 60-min 
trial in an open field chamber (41 cm x 41 cm x 30 cm) crossed by a grid of photobeams 
(VersaMax system, AccuScan Instruments).  Counts were taken of the number of 
photobeams broken during the trial in 5-min intervals, with measures for total distance 
traveled, rearing movements, and time spent in the center region.   
 
Rotarod.  Subjects were tested for motor coordination and learning on an accelerating 
rotarod (Ugo Basile, Stoelting Co., Wood Dale, IL).  For the first test session, animals were 
given 3 trials, with 45 seconds between each trial.  Two additional trials were given 48 
hours later.  Rpm (revolutions per minute) was set at an initial value of 3, with a 
progressive increase to a maximum of 30 rpm across 5 min (the maximum trial length).  
Measures were taken for latency to fall from the top of the rotating barrel.   
 
Morris water maze.  The visible platform task was used to assess swimming ability and 
visual function.  The water maze consisted of a large circular pool (diameter = 122 cm) 
partially filled with water (45 cm deep, 24-26o C), located in a room with numerous visual 
cues.  Each mouse was given 4 trials per day, across 3 days, to swim to an escape platform 
cued by a patterned cylinder extending above the surface of the water.  For each trial, the 
mouse was placed in the pool at 1 of 4 possible locations (randomly ordered), and then 
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given 60 seconds to find the visible platform.  If the mouse found the platform, the trial 
ended, and the animal was allowed to remain 10 seconds on the platform before the next 
trial began.  If the platform was not found, the mouse was placed on the platform for 10 
seconds, and then given the next trial.  Measures were taken of latency to find the platform, 
swimming speed, and swimming distance via an automated tracking system (Noldus 
Ethovision).      
 
Hargreaves assay.  Heat sensitivity was measured by heating each hindpaw once per day 
using the Plantar Test apparatus (IITC) with a cut-off time of 20 seconds.  
 
Immunohistochemistry.  For immunohistochemistry experiments, mice were 
anesthetized using isoflurane and transcardially perfused with 4% paraformaldehyde. The 
mice were then decapitated, and the brains were post-fixed in 4% paraformaldehyde 
overnight. All of the stained sections were obtained from identical regions of the brain that 
were carefully selected based on structural and anatomical landmarks. Paraffin-embedded 
sections were used for hematoxylin-eosin (H/E), cleaved caspase-3, NeuN, Bcl-xL, and 
PCNA, and RFP stains. Briefly, IHC was carried out in the Bond Autostainer (Leica 
Microsystems Inc. Norwell, MA 02061). Slides were dewaxed in Bond Dewax solution 
(Leica, part #AR9222) and hydrated in Bond Wash solution (Leica, catalog #AR9590). 
Antigen retrieval was performed for 30 min at 100ºC in Bond-Epitope Retrieval solution 1 
pH-6.0 (AR9961).  Slides were incubated with the RFP, Bcl-xL, PCNA, cleaved caspase-3, 
NeuN, Bax, and Bak primary antibodies for 1 hour. DAPI or hematoxylin was used as a 
nuclear stain. Antibody detection was performed using the Bond Polymer Refine Detection 
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System (DS9800). Stained slides were dehydrated and coverslipped. Representative images 
are obtained from independent experiments, done at least in triplicate.  
 
For all other stains, wildtype and Bcl-xL-deficient brains were embedded in 4% low-
melting-point agarose in 1x PBS and were sectioned coronally (50 µm) on a vibratome 
(Leica VT 1200S). The following antibodies were used for immunohistochemistry on 
vibratome sections: cleaved caspase-3 (catalog #9664, Cell Signaling), Cux1 (catalog #sc-
13024, Santa Cruz Biotechnology), Brn1 (kind gift from A. Ryan, McGill University), Tbr1 
(catalog # ab31940, Abcam), NeuN (catalog #MAB377, Millipore).  Appropriate anti-mouse, 
anti-rabbit, anti-rat, or anti-guinea pig secondary antibodies were used to detect primary 
antibody binding. DAPI was used as a nuclear stain. Representative images are obtained 
from independent experiments, done at least in triplicate.  
 
Statistics. Statistical analyses were performed using GraphPad Prism 5 or Statview 5.0.1 
(SAS)  software. Ex vivo data are obtained from at least three independent experiments and 
expressed as mean ± s.e.m. unless otherwise specified. The Student’s t-test (unpaired, two-
tailed) for parametric data was used for analysis of two groups. Behavioral data were 
analyzed using 1-way, 2-way, or repeated measures ANOVAs, with the factors genotype and 
sex.  Fisher's protected least-significant difference (PLSD) tests were used for comparing 
group means only when a significant F value was determined.  No statistical methods were 
used to predetermine sample sizes, but our sample sizes are consistent with those reported 
in previous publications. 
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2.6 Figures and Legends 
 
Figure 2.1: Loss of Bcl-xL in the dorsal telencephalon results in microcephaly. 
 
(A) tdTomato+/Cre- (rosa26reporter-tdTomato; no Cre control) and tdTomato+/Cre+ 
(Emx1-Cre; rosa26reporter-tdTomato) brains at E12.5 stained with RFP show the 
recombination pattern of the Emx1-Cre line. Scale bar denotes 100 µm. (B) Wildtype and 
Bcl-xLEmx1-Cre mouse cortices stained with Bcl-xL at postnatal day 1 (P1). Samples were 
counterstained with hematoxylin. Scale bar denotes 50 µm.  (C) Wildtype and Bcl-xLEmx1-Cre 
mice at P1. (D) Images of brains and (E) brain weights of P1 wildtype and Bcl-xLEmx1-Cre 
mice. (F) Wildtype and Bcl-xLEmx1-Cre mice at P25. (G) Images of brains and (H) brain 
weights of P25 wildtype and Bcl-xLEmx1-Cre mice.  Data shown are means ± s.e.m. for each 
group. ** P<0.01; n.s. = not significant. 
  
 68 
 
Figure 2.1 
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Figure 2.2: Bcl-xL deletion in the brain causes a reduction in cortical thickness by 
P30. 
 
(A) Wildtype and Bcl-xLEmx1-Cre mouse brains stained with DAPI at P1. Quantification of the 
cortical thickness is shown in (B). (C) Wildtype and Bcl-xLEmx1-Cre mouse brains stained 
with DAPI at P7.  Quantification of the cortical thickness is shown in (D). (E) Wildtype and 
Bcl-xLEmx1-Cre mouse brains stained with DAPI at P30.  Quantification of the cortical 
thickness is shown in (F). (G) Wildtype and Bcl-xLEmx1-Cre mouse brains stained with NeuN 
((neuronal marker) at P30.  CTX = cortex; HC = hippocampus. Scale bars in A, C and E 
denote 50 µm. Data shown are means ± s.e.m. for each group. ** P<0.01; *** P<0.0001; n.s. = 
not significant. 
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Figure 2.2 
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Figure 2.3: Bcl-xL deletion leads to cell death in postmitotic neurons. 
 
(A) Brains of wildtype and Bcl-xLEmx1-Cre mice at gestational day 16 (E16) stained with Bcl-
xL. (B) Cortex of wildtype mice at E16 stained with a marker of proliferation, PCNA (red), 
and Bcl-xL (green). Scale bar denotes 50 µm. (C) Quantification of Bcl-xL in PCNA-positive 
and PCNA-negative cells shown in B. (D) Brains of wildtype and Bcl-xLEmx1-Cre mice at E16 
co-stained with NeuN (green), cleaved caspase-3 (red), and DAPI. (E) Quantification of the 
number of cleaved caspase-3-positive cells in the NeuN-negative and NeuN-positive 
populations in the Bcl-xLEmx1-Cre cortex. Scale bar denotes 25 µm. (F) Cortices of wildtype 
and Bcl-xLEmx1-Cre mice at E16 stained with cleaved caspase-3, PCNA, and DAPI.  The image 
on the right is a magnified image of the cortex (dotted white box).  Scale bar denotes 300 
µm. (G) Quantification of the number of cleaved caspase-3-positive and PCNA-positive cells 
shown in (G). (H) Quantification of the number of cleaved caspase-3-positive and PCNA-
negative cells shown in (F). Data shown are means ± s.e.m. for each group. * P<0.05, ** 
P<0.01, *** P<0.001; n.s. = not significant. 
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Figure 2.3 
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Figure 2.4: Bcl-xL is critical for the survival of specific populations of cortical 
neurons. 
 
(A) Cortices of P1 wildtype and Bcl-xLEmx1-Cre mice stained with cleaved caspase-3, a marker 
of apoptosis. (B) Quantification of the number of cleaved caspase-3-positive cells shown in 
(A). (C) Presence of pyknotic nuclei in the cortex of Bcl-xLEmx1-Cre mice. Inset, magnified 
image of the white box in the cortex. White arrows denote pyknotic nuclei. (D) 
Quantification of the number of pyknotic nuclei shown in (C).  (E) Hippocampus of P1 
wildtype and Bcl-xLEmx1-Cre mice stained with cleaved caspase-3.  (F) Hippocampus of P1 
wildtype and Bcl-xLEmx1-Cre mice stained with DAPI reveal the presence of pyknotic nuclei.  
Inset, magnified image of the white box in the hippocampus. White arrows denote pyknotic 
nuclei.  Cortices of P30 wildtype and Bcl-xLEmx1-Cre mice co-stained with DAPI and (G) Cux1; 
(I), Brn1; and (K), Tbr1. Quantification of the number of (H) Cux1-positive cells; (J), Brn1-
positive cells; and (L), Tbr1-positive cells. Data shown are means ± s.e.m. for each group. 
CTX = cortex; HC = hippocampus.  The wildtype image in (G) shows the cortex and the top 
region of the hippocampus in the wildtype and Bcl-xLEmx1-Cre mice.  Scale bars in (A), (C), 
(E), (F), (G), (I), and (K) denote 50 µm.  * P<0.05 and ** P<0.01. 
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Figure 2.4 
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Figure 2.5: Loss of Bcl-xL leads to a smaller but functional retinotopic map in the 
visual cortex. 
 
(A) Microcephaly in Bcl-xLEmx1-Cre mice. Tilted rectangles depict the in vivo imaging field-of-
view.  V1 = primary visual cortex, SC = superior colliculus. (B) Retinotopic maps acquired 
with in vivo imaging of visually-evoked responses to horizontal (left) and vertical (right) 
bars in wildtype and Bcl-xLEmx1-Cre mice. (C, D) Quantification of the entire V1 area and the 
area within it that represents a 50-degree space in visual field in wildtype and Bcl-xLEmx1-Cre 
mice.  Data shown are means ± s.e.m. for each group. * P<0.05, ** P<0.01, *** P<0.001. 
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Figure 2.5 
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Figure 2.6: The apoptotic cell death and microcephaly in Bcl-xLEmx1-Cre mice can be 
rescued with co-deletion of Bax and Bak. 
 
Cortices of P1 wildtype and Bcl-xLloxP/loxP BaxloxP/loxP Emx1-Cre Bak-/- triple knockout (BBB 
TKO) mice stained with (A) Bcl-xL; (B) Bax; and (C) Bak. Scale bars in (A), (B) and (C) 
denote 50 µm. (D) Cortices from P1 wildtype, Bcl-xLEmx1-Cre (Bcl-xL KO), and BBB TKO mice 
stained with cleaved caspase-3 and DAPI. Quantification of the number of cleaved caspase-
3-positive cells is shown in (E). (F) Wildtype, Bcl-xL KO, and BBB TKO brains co-stained 
with NeuN and DAPI. (G) Cortical thickness in P30 wildtype, Bcl-xL KO, and BBB TKO 
brains. Quantification of the number of NeuN-positive cells is shown in (H). (I) Cortices 
from P30 wildtype, Bcl-xL KO, and BBB TKO mice stained with Cux1 and DAPI. (J) 
Quantification of the number of Cux1-positive cells is shown. Data shown are means ± 
s.e.m. for each group. Scale bars in (D), (F) and (I) denote 50 µm. ** P<0.01, *** P<0.001. 
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Figure 2.6 
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Figure 2.7: Loss of Bcl-xL selectively in postmitotic neurons results in reduced body 
and brain weights and cell death in the upper regions of the cortex. 
 
(A) Photos of wildtype and Bcl-xLNex-Cre mice at P30. (B) Body weights of wildtype and Bcl-
xLNex-Cre male mice at P30. (C) Images of brains isolated from wildtype and Bcl-xLNex-Cre 
mice at P30. (D) Brain weights of wildtype and Bcl-xLNex-Cre male mice at P30. (E) Cortices 
of P1 wildtype and Bcl-xLNex-Cre mice stained with cleaved caspase-3.  (F) Quantification of 
the number of cleaved caspase-3-positive cells shown in (E). Scale bar in (E) denotes 25 
µm. * P<0.05; *** P<0.0001. 
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Figure 2.7 
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Figure 2.8: Bcl-xLNex-Cre mice display self-inflicted skin lesions.  
 
(A) Bcl-xLNex-Cre mice spend significantly greater periods of time undergoing hindlimb 
clasping. Analyses were conducted on P30 wildtype and Bcl-xLNex-Cre mice. (B) 
Quantification of the number of seconds P30 wildtype and Bcl-xLNex-Cre mice display 
hindlimb clasping over a three-minute period. Hindlimb clasping was examined in n = 3 
wildtype and n = 3 Bcl-xLNex-Cre mice. (C) Severe skin lesions observed in the hindlimb of 
Bcl-xLNex-Cre mice. Lesions began to appear at approximately one month of age. (D) 
Percentage of time spent grooming in wildtype and Bcl-xLNex-Cre mice.  (E) Withdrawal 
latency (seconds) in wildtype and Bcl-xLNex-Cre mice on the Hargreaves apparatus. Data 
shown are means ± s.e.m. for each group. * P<0.05; ** P<0.01; *** P<0.0001; n.s. = not 
significant. 
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Figure 2.8 
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Figure 2.9: Bcl-xLNex-Cre mice exhibit numerous neurobehavioral deficits. 
 
(A) 60-minute open field analyses reveal that both male and female Bcl-xLNex-Cre mice travel 
significantly greater distances compared to wildtype animals. Both male and female Bcl-
xLNex-Cre mice exhibit similar number of rears (B) and spend similar amounts of time in the 
center of the open field as compared to wildtype mice (C).  (D) Percentage of time spent in 
the open arms of the elevated plus maze by wildtype and Bcl-xLNex-Cre mice. (E) Percentage 
of entries into the open arms of the elevated plus maze by wildtype and Bcl-xLNex-Cre mice. 
(F) Total number of entries into the open arms of the elevated plus maze by wildtype and 
Bcl-xLNex-Cre mice. G, Latency to fall from an accelerating rotarod.  Latency (H) and speed (I) 
in reaching the visible platform in the Morris water maze task in wildtype and Bcl-xLNex-Cre 
mice. Data shown are means ± s.e.m. for each group. * P<0.05. 
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Figure 2.9 
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CHAPTER THREE: MICRORNA-29 IS AN ESSENTIAL REGULATOR OF DNA 
METHYLATION DURING BRAIN MATURATION 
3.1 Overview 
 
  While early brain development and neurodegeneration have been examined 
extensively, the events that govern brain maturation are less understood.  During postnatal 
development, the number of neurons remains relatively constant (Bandeira et al. 2009; Fu 
et al. 2013), but widespread changes in synaptic connectivity are evident (Stiles and 
Jernigan 2010).  Importantly, perturbations of synaptic development or maturation during 
this period can have severe neurobehavioral consequences as seen in autism spectrum 
disorders (ASD), obsessive-compulsive disorders and schizophrenia (Blakemore 
2008).  Recent studies have led to the unexpected discovery that marked increases in 
noncanonical (non-CG) DNA methylation occur during brain maturation (Xie et al. 2012; 
Lister et al. 2013a; Guo et al. 2014; Chen et al. 2015; Gabel et al. 2015; Mo et al. 2015).  This 
de novo CH methylation (where H= A, C, T), which occurs 1-4 weeks postnatally in mice and 
1-15 years in humans (Lister et al. 2013a), is important as binding of MeCP2 to CH-
methylated DNA mediates the repression of many neuronal genes (Chen et al. 2015; Gabel 
et al. 2015); consequently, loss or duplication of MeCP2 leads to intellectual and behavioral 
disabilities (Lombardi et al. 2015).  Thus, the levels of CH methylation need to be strictly 
balanced in the maturing brain.  The critical period of CH methylation appears to be 
mediated by Dnmt3a, the DNA methyltransferase that catalyzes CH methylation (Guo et al. 
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2014; Gabel et al. 2015).  During brain maturation, Dnmt3a levels are elevated and then 
sharply decline (Feng et al. 2005; Lister et al. 2013a).  Here we identify miR-29 as an 
essential regulator of Dnmt3a and CH methylation during brain maturation.  Mice deficient 
in miR-29 exhibit enhanced levels of Dnmt3a, global CH hypermethylation, and  an 
increased repression of neuronal genes in the mature brain.  As a consequence, the miR-29-
deficient mice appear normal at birth, but subsequently displayed excitatory-inhibitory 
(E/I) imbalance and an increased susceptibility to seizures.  These mice also exhibit severe 
neurological deficits including hyperactivity and compulsive overgrooming as well as early 
lethality.  Together, these results identify an essential function of miR-29 in defining the 
critical period of DNA methylation during brain maturation, the absence of which results in 
multiple neurobehavioral deficits. 
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3.3 Results 
Several recent studies have identified a critical period during postnatal mammalian 
brain development during which there is a dramatic increase in the methylation of the 
neuronal genome at CH sequences (Xie et al. 2012; Lister et al. 2013a; Guo et al. 2014; Chen 
et al. 2015; Gabel et al. 2015; Mo et al. 2015).  These methylCH (mCH) marks have been 
hypothesized to control the generation of neuronal diversity by regulating gene 
transcription across the genome.  In the mouse, mCH is catalyzed by the enzyme Dnmt3a, 
and the deposition of mCH marks peak during the first few weeks of life (Guo et al. 2014; 
Gabel et al. 2015).  The time course of mCH deposition in postnatal neurons is tightly 
controlled such that the level of Dnmt3a begins to decrease significantly several weeks 
after birth (Feng et al. 2005; Lister et al. 2013b).  This decrease in Dnmt3a results in a 
cessation in the deposition of additional mCH marks, and  may be  important for proper 
brain maturation as mutations in Dnmt3a,  as well as the methyl binding protein MeCP2 
that binds to mCH, are associated with devastating disorders of postnatal brain 
development (Gabel et al. 2015; Lombardi et al. 2015).  However, the mechanisms that 
regulate the activation and subsequent repression of Dnmt3a expression, and the proper 
deposition of mCH marks during  postnatal brain development have not yet been identified. 
MicroRNAs (miRNAs), which have the potential to post-transcriptionally silence 
hundreds of genes, are known to modulate neurodevelopment (Petri et al. 2014) and 
neurodegeneration (Abe and Bonini 2013).  To determine if Dnmt3a expression during 
brain maturation and, in particular, the decrease in Dnmt3a expression that occurs at the 
closure of the critical period of CH methylation, is mediated by a miRNA(s) we examined 
the 3’ untranslated (UTR) region of the mouse Dnmt3a gene for consensus binding sites for 
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miRNAs (Fig. 3.1).  To focus on the specific miRNA(s) that could be important for inhibiting 
Dnmt3a expression in the mature brain, we conducted an unbiased small RNA sequencing 
analysis to identify miRNAs that are induced during brain maturation.  For this analysis we 
employed the mouse cerebellum, as the timeline for cerebellar postnatal development is 
well defined.  Cerebellar granule neuron precursors (CGNPs) undergo rapid proliferation 
and complete their differentiation into cerebellar granule neurons (CGNs) by postnatal day 
18 (P18) (Hatten and Roussel 2011) (Fig. 3.2). Thus, we probed for miRNAs that are 
differentially expressed between young (P18) and adult (P250) cerebella.  The most 
upregulated miRNAs during this period all belonged to the miRNA-29 (miR-29) family, 
which were strikingly increased approximately 80 fold (Fig. 3.3A).  The miR-29 family 
consists of three members—miR-29a, miR-29b and miR-29c—that are expressed from two 
genomic loci: miR-29ab1 and miR-29b2c (Kriegel et al. 2012).  Quantitative PCR analysis 
for miR-29b, which is expressed from both of these loci, confirmed that the marked 
increase in miR-29 was most evident during cerebellar maturation (Fig. 3.3B).  This 
increase in miR-29b expression is even more evident in the cortex where the expression of 
miR-29 is very low during the embryonic period but increases significantly postnatally (Li 
et al. 2014a) during the period of brain maturity (Fig. 3.3C).  The observation that miR-29 
expression increases significantly in the postnatal period was of particular interest given 
that Dnmt3a has multiple evolutionarily conserved binding sites in its 3’ UTR (Fig. 3.1) and 
has previously been shown to be regulated by miR-29 (Fabbri et al. 2007; Pandi et al. 
2013).  Consistent with this idea, the marked increase in miR-29 beyond P20 is coincident 
with the sharp decrease in Dnmt3a expression that occurs during this period (Feng et al. 
2005; Lister et al. 2013a).   
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To determine if miR-29  regulates Dmnt3a expression and function during brain 
maturation in vivo, we generated mice that were floxed for both alleles of miR-29.  
Specifically, miR-29a/b1f/f and miR-29b2/cf/f mice were crossed together to generate mice 
where all three members of the miR-29 family could be deleted in the presence of a Cre 
driver. To globally delete miR-29, we crossed these mice with CMV-Cre-expressing mice 
(hereafter referred to as miR-29CMV) (Fig. 3.4A, B). These mice were born at the expected 
Mendelian ratio, appeared normal at birth and were indistinguishable from wildtype 
littermate controls at postnatal day 10. However, starting at 10 days, the miR-29 knockouts 
begin to exhibit retarded growth, become ataxic, and die by 30 days of age (Fig. 3.3D-F).  To 
specifically examine the importance of miR-29 in the brain, we used the Nestin-Cre mice to 
conditionally delete miR-29 in the brain (hereafter referred to as miR-29Nestin) (Fig. 3.4C-E).  
The miR-29Nestin mice were also born normally and exhibited the same growth retardation 
and ataxia as miR-29CMV mice, with most mice dying by 40 days (Fig. 3.3G-I).  The lethality 
seen with miR-29 deletion was dose-dependent as mice with partial deletion of miR-29 
survived longer (Fig. 3.5).  Ataxia and motor dysfunction have previously been observed 
when only a subset of the miR-29 family was targeted, either with miR-29a- and miR-29b-
specific locked nucleic acids (LNAs) or deletion of only the miR-29ab1 cluster (Roshan et al. 
2014; Papadopoulou et al. 2015).  Moreover, consistent with the finding that miR-29 is not 
expressed during the stages of early brain development, miR-29Nestin mice did not exhibit 
any gross developmental brain abnormalities (Fig. 3.6, 3.7).  We also found no defects in 
intrinsic cell parameters such as resting membrane potential or the ability to generate 
action potentials in miR-29-deficient neurons (Fig. 3.8).  Thus, fundamental aspects of early 
brain development were not affected by the absence of miR-29.  The fact that the brain-
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specific deletion of miR-29 recapitulates the ataxia, growth retardation and lethality seen 
with global deletion of miR-29 suggests that the essential function of miR-29 is in the 
maturing brain.   
To  determine if miR-29 is required for  the downregulation of Dnmt3a expression 
in the maturing brain, we examined Dnmt3a levels in miR-29-deficient brains.  Dnmt3a, 
both at the transcript and protein levels, were markedly elevated in miR-29Nestin mice at 
P40 (Fig. 3.9A, B, 3.10). A potential consequence of sustained Dnmt3a levels in the brains of 
miR-29-deficient animals is persistent DNA methylation. To investigate whether DNA is 
hypermethylated in the brains of miR-29Nestin mice, we conducted whole-genome bisulfite 
sequencing analysis on P40 wildtype and miR-29Nestin mice. Strikingly, loss of miR-29 in the 
brain led to significantly greater levels of CH methylation during brain maturation (Fig. 
3.9C). CH methylation in the mature brain is predominantly known to occur at CA sites (Xie 
et al. 2012; Lister et al. 2013a; Guo et al. 2014; Kinde et al. 2015), a pattern consistent with 
the finding in miR-29-deficient brains.  We did not detect any increases in CG methylation 
in miR-29-deficient brains (Fig. 3.11).  Importantly, the increase in CH methylation in the 
miR-29-deficient mice occurred at sites normally methylated in the maturing brain (Fig. 
3.9D).   
CH methylation, which mediates gene repression in neurons, is important for fine 
tuning neuronal gene expression during brain maturation.  To gain insight into the specific 
pathways affected in the miR-29-deficient mice, we conducted a gene array analysis of 
cortical samples from wildtype and miR-29Nestin mice and found 444 annotated genes to be 
differentially expressed (226 upregulated genes, 218 downregulated genes, FDR < 0.1) (Fig. 
3.9E).  As expected, an unbiased query identified miR-29 as the miRNA predicted to target 
 91 
 
the largest number of upregulated genes in this gene set (e.g. of the 226 upregulated genes, 
31 genes are predicted direct targets of miR-29, including Dnmt3a and the Wnt/β-catenin 
pathway (Shin et al. 2014b)) (Fig. 3.9F, Fig. 3.10).  Importantly, consistent with our 
observation that miR-29-deficient brains have hypermethylated DNA, a large number of 
key neuronal genes associated with defects in synaptic neurotransmission, OCD, autism-
spectrum disorders, and susceptibility to seizures were markedly downregulated in miR-
29-deficient brains (Fig. 3.9G).  These include multiple GABA receptor subunits, Shank3 
and Cntnap2. Also downregulated was RPS6KA3 (RSK2), mutations of which are associated 
with Coffin-Lowry syndrome, in which patients exhibit OCD and autism-related deficits 
(Trivier et al. 1996).  Further analysis revealed that these repressed neuronal genes were 
indeed hypermethylated in the miR-29 deficient brains (Fig. 3.9H). 
Many of the genes we found to be hypermethylated in the miR-29-deficient brain 
are also linked to diseases associated with excitatory-inhibitory (E/I) imbalance 
(Rubenstein and Merzenich 2003; Penagarikano et al. 2011).  Thus, we examined whether 
miR-29 deficiency induced an E/I imbalance in the brain.  Indeed, we found that the 
number of inhibitory interneurons (GABA-, NPY-, calretinin-, and calbindin-positive cells) 
was globally decreased throughout the cortex in miR-29Nestin mice (Fig. 3.12A-D). 
Interestingly, miR-29Nestin mice also displayed an increase in the number of Cux1-positive 
excitatory projection neurons throughout layers II/III of the cortex as compared to brains 
from wildtype mice (Fig. 3.12E).  Thus, miR-29 expression is important for maintaining the 
excitatory/inhibitory balance in the cortex which, with miR-29 deficiency, shifts the brain 
towards an excitatory phenotype. 
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To probe the consequences of this increased excitatory phenotype, we examined 
whether the miR-29-deficient mice were more susceptible to seizures. Kainic acid, a 
structural analog of glutamate, is known to induce an epileptiform state in the brain by 
disrupting the E/I balance of neurons. All miR-29Nestin mice displayed Racine seizure scale 
characteristics and underwent tonic-clonic seizures within 15 minutes of kainic acid 
injection (30mg/kg, intraperitoneal), while no wildtype animals exhibited tonic-clonic 
seizures during this time frame (Fig. 3.12F, G).  Importantly, following tonic-clonic seizures, 
all miR-29Nestin mice, but none of the wildtype mice, died within 20 minutes of kainic acid 
injection (Fig. 3.12G).   
Lastly, to examine whether the disruption of miR-29 expression, the prolonged 
expression of Dnmt3a, and/or the enhanced methylation of CH sequences during brain 
maturation might lead to behavioral abnormalities, we conducted a variety of assessments 
in miR-29-deficient mice.  Upon tail suspension, while wildtype mice displayed flailing 
hindlimb movements, miR-29Nestin mice exhibited hindlimb clasping—a common sign of a 
neurological defect (Fig. 3.13A).  In a two-minute test, miR-29Nestin mice spent significantly 
longer periods of time clasping their hindlimbs compared to wildtype controls (Fig. 3.13B). 
Importantly, both miR-29Nestin and miR-29CMV mice demonstrated repetitive, excessive self-
grooming behavior by 20 days of age, leading to facial hair loss and self-inflicted ulcerative 
skin lesions (Fig. 3.13C, 3.14A). These lesions were first observed 10-15 days after the 
onset of over-grooming in the miR-29 knockout mice and appeared primarily in the facial 
area, with a subset of mice grooming extensively around the eyes such that the orbital area 
became inflamed and bled.  The self-inflicted lesions were paradoxically more severe in 
mice with partial deletion of miR-29 as these mice lived longer and, thus, sustained longer 
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periods of excessive grooming (Fig. 3.13D, 3.14B).  The abnormal repetitive grooming was 
often exacerbated upon animal handling and after transferring the animals to a novel 
environment.  In this context, miR-29Nestin mice spent 40% of the time grooming, compared 
to 10% for wildtype controls (Fig. 3.13E).  
Upon further assessing for hyperkinetic behavior, open field analyses revealed that 
deletion of miR-29 leads to overt hyperactivity with increases in the total distance traveled 
as well as greater numbers of fine movements, a measure of stereotypic behavior (Fig. 
3.13F, G). miR-29Nestin mice also spend significantly more time in the center region 
compared to wildtype controls, suggesting a loss of typical cautionary avoidance of a novel 
open area (Fig. 3.13H).  Clinical studies have found that patients with autism spectrum 
disorders have impaired sensorimotor gating (Perry et al. 2007).  Therefore, we evaluated 
wildtype and miR-29Nestin mice for prepulse inhibition (PPI) in an acoustic startle test. In 
line with findings from the human studies, the miR-29Nestin mice exhibited profound PPI 
deficits at almost every decibel level (Fig. 3.13I).  Additionally, both grip strength and 
motor coordination were impaired in the miR-29Nestin mice, the latter of which is consistent 
with the progressive ataxia observed in these mice (Fig. 3.13J, K). These findings show that 
loss of miR-29 leads to numerous neurobehavioral abnormalities including a striking 
hyperkinetic phenotype. 
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3.4 Discussion 
While brain maturation is recognized as a period during which experience can fine 
tune neuronal activity, the epigenetic mechanisms by which this is achieved are just 
starting to become uncovered.  A major clue has come from recent studies that found 
marked increases in Dnmt3a-dependent noncanonical (CH) DNA methylation in the 
maturing brain (Xie et al. 2012; Lister et al. 2013a; Guo et al. 2014; Chen et al. 2015; Gabel 
et al. 2015; Mo et al. 2015).  Our results reveal that miR-29 regulates a critical period 
during which neuronal genes are epigenetically methylated in the maturing brain.  In the 
absence of miR-29, Dnmt3a levels remain elevated and DNA is hypermethylated at CH 
sequences in the mature brain.  
mCH (predominantly mCA) in DNA is recognized by MeCP2, a protein that functions 
to mediate transcriptional repression of neuronal genes. As a consequence, genes that are 
methylated at CH sites during brain maturation are preferentially reduced with MeCP2 
duplication (Chen et al. 2015; Gabel et al. 2015), a phenomenon that we also observe with 
hypermethylated DNA in the miR-29-deficient brains.  Interestingly, mice overexpressing 
MeCP2 develop multiple neurological abnormalities that are also strikingly similar to the 
defects observed in our miR-29-deficient mice, including hyperactivity, decreased anxiety, 
seizures, as well as premature death (Lombardi et al. 2015).   The fact that both MeCP2-
overexpressing mice and miR-29-deficient mice appear normal at birth but then 
progressively deteriorate illustrates the essential role that these molecules play selectively 
during brain maturation.  The relevance of regulating CH methylation and fine-tuning 
neuronal gene expression in humans is underscored by the fact that both the loss or 
duplication of MeCP2 result in Rett syndrome or intellectual disability, 
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respectively(Lombardi et al. 2015).  Likewise, dysregulation of miR-29 is associated with 
psychiatric disorders such as schizophrenia and bipolar disorder (Geaghan and Cairns 
2015).   
The complex phenotype of the miR-29-deficient mice could be attributed to a 
number of key neuronal genes that are epigenetically hypermethylated and repressed in 
the absence of miR-29.  For example, loss of GABA receptor activity is associated with 
numerous neurodevelopmental disorders including autism, Angelman Syndrome, 
schizophrenia, Fragile X syndrome and epilepsy (Braat and Kooy 2015).  In addition, 
Shank3 and Cntnap2, both of which are downregulated in the miR-29-deficient brain, are 
associated with autism (Peca et al. 2011; Penagarikano et al. 2011).  Mice deficient in 
Shank3 exhibit repetitive grooming and OCD-like behavior (Peca et al. 2011), whereas mice 
deficient in Cntnap2 have ectopic Cux1-positive cells in the cortex and exhibit spontaneous 
epileptic seizures (Penagarikano et al. 2011).   The fact that both of these phenotypes are 
manifested in the miR-29-deficient mice highlights the central importance of this single 
miRNA family in modulating these diverse pathways in the brain. 
Together, these results not only identify an essential function of miR-29 as a key 
driver that regulates DNA methylation during brain maturation, but they also highlight why 
restricting DNA methylation during a critical window is important for sustaining a 
functional, mature brain. 
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3.4 Materials and Methods 
Mice. The miR-29ab1 floxed allele was generated by homologous recombination and 
genomic targeting. A 827 bp gene segment containing miR-29a and miR-29b1 was cloned 
from genomic DNA of 129/SvEv mice. To amplify the long arm (LA) and short arm (SA), a 
BAC clone (RP24-248C11) was used as the PCR template. LA, SA and the miR-29ab1 gene 
segment were cloned into the PGKneoF2L2DTA backbone. The targeting vector was 
sequenced and confirmed to have no sequence mutation compared with the genomic DNA 
sequence listed in NCBI database. Targeting vectors were linearized by SacII (New England 
BioLabs) restriction enzyme digestion and were used for microinjection. ES cells from 
129/SvEv-B6 mice were microinjected and positively selected in neomycin-containing 
medium, and successful genomic targeting was confirmed by PCR. The transgenic 
procedure was performed by the Duke Transgenic Mouse Facility. Animals were bred and 
maintained in the SPF facility managed by Duke University Division of Laboratory Animal 
Research. All animal procedures were approved by the Duke University Institutional 
Animal Care and Use Committee. Similar procedures were used to generate miR-29b2c 
conditional knockout mice as described above. In brief, a 817 bp gene fragment containing 
miR-29b2 and miR-29c was cloned from genomic DNA of 129/SvEv mice. LA and SA were 
PCR amplified from a BAC clone (RP23-465H4), and were cloned into the PGKneoF2L2DTA 
targeting vector. 
The above mice were bred to generate mice floxed at both genomic loci (miR-
29abloxP/loxP; miR-29 bcloxP/loxP mice). Conditional deletion of miR-29 was carried out by 
crossing the above mice with various Cre lines. Two different Cre lines—Nestin-Cre and 
CMV-Cre—were used to inactivate miR-29. Nestin-Cre and CMV-Cre were obtained from 
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Jackson Laboratories.  Mice were maintained in a 12 hr light, 12 hr dark cycle (lights on at 
7AM, lights off at 7 PM). All animal handling and protocols were carried out in accordance 
with established practices as described in the National Institutes of Health Guide for Care 
and Use of Laboratory Animals and as approved by the Animal Care and Use Committee of 
the University of North Carolina (UNC). 
 
Small RNA sequencing and analysis. Libraries for Illumina sequencing were prepared 
using a modification of the TruSeq protocol.  Briefly, 1 ug total RNA was ligated to 3 pmol of 
the 3' linker using T4 RNA ligase 2. RNA size fractions corresponding to 35- 70 nucleotides 
(insert plus linker) were gel isolated and ligated to 3 pmol 5' linker.  Products were reverse 
transcribed, PCR amplified to mid-log phase, and size isolated.  Libraries were barcoded 
using indexed 5' linkers.  Libraries were sequenced on an Illumina HiSeq 2000 to ~20 
million reads per barcode. Small RNA libraries are aligned to mm9 genome. microRNA 
annotations were downloaded from miRBase r18.  
 
Bisulfite sequencing. Genomic DNA was extracted with the Blood and Tissue DNeasy kit 
and sonicated with a covaris to 200 bp. Unmethylated lambda DNA was spiked in (0.5% 
(w/w)). Whole genome bisulfite sequencing was performed similarly as described(Mo et al. 
2015) except that the EZ DNA methylation-gold kit (Zymo) was used for bisulfite 
conversion. Libraries were sequenced on a Miseq by performing a 75x2 cycle run. 
BSmap(Xi and Li 2009) was used to map reads and only uniquely mapping reads were 
retained for analyses. Methylation levels were determined by calculating #C/(#C+#T). 
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Affymetrix gene array. RNA was extracted from cerebella and cortices using the Qiagen 
miRNeasy kit (catalog #217004) using the manufacturer’s instructions. Total RNA (250 ng) 
was used to synthesize fragmented and labeled sense-strand cDNA and hybridize onto 
Affymetrix arrays. The Affymetrix GeneChip® WT PLUS Reagent Kit Manual was followed 
to prepare the samples. Briefly, the GeneChip® WT PLUS Reagent Kit (Affymetrix) was 
used to generate sense-strand cDNA from total RNA.  Following synthesis of sense-strand 
cDNA, the cDNA was fragmented and labeled with the kit. Fragmented and labeled cDNA 
was used to prepare a hybridization cocktail with the Affymetrix GeneTitan Hybridization 
Wash and Stain Kit for WT Arrays. Hybridization, washing, staining and scanning of the 
Affymatrix peg plate arrays was carried out using the Affymetrin GeneTitan MC Instrument. 
GeneChip Command Console Software (AGCC) was used for GeneTitan Instrument control.  
Affymetrix Expression Console Software was used for basic data analysis and quality 
control. 
 
 
miRHub analysis. First, we used the seed-based target prediction algorithm TargetScanS 
5.2(Grimson et al. 2007) to determine for each miRNA the number of predicted conserved 
targets among the genes in our gene sets. Each predicted miRNA-gene interaction was 
assigned a score based on the strength of the seed match, the level of conservation of the 
target site, and the clustering of target sites within that gene’s 3′-UTR. Additionally, the 
score for each gene was weighted according to the number of high-confidence protein-
protein interactions reported in the STRING 9.0 database(Szklarczyk et al. 2011). Finally, 
for each miRNA, the final targeting score was calculated by summing the scores across all 
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genes and dividing by the number of genes. We repeated this procedure 10,000 times, with 
a new set of randomly selected mouse genes each time, in order to generate a background 
distribution of the predicted targeting scores for each miRNA (genes and corresponding 3′-
UTR sequences were downloaded from http://www.targetscan.org). These score 
distributions were then used to calculate an empirical p-value of the targeting score for 
each miRNA in our gene set. Genes were selected at random from a pool with similar 
overall connectivity to the genes in our gene set, and to account for differences in the 
average 3′ UTR length between the genes of interest and the randomly selected genes in 
each simulation, the targeting score was normalized by 3′ UTR length.  
 
Bioinformatics. 3’ UTRs of significantly up- and down-regulated genes were analyzed for 
enrichment of predicted miRNA target sites as previously described(Baran-Gale et al. 
2013). 
 
Mouse Behavioral Analysis 
Open field test.  Exploratory activity in a novel environment was assessed by a 60-minute 
trial in an open field chamber (41 cm x 41 cm x 30 cm) crossed by a grid of photobeams 
(VersaMax system, AccuScan Instruments).  Counts were taken of the number of 
photobeams broken during the trial in five-minute intervals, with separate measures for 
total distance traveled and fine movements (the repeated breaking of the same set of 
photobeams).  Time spent in the center region of the open field was measured as an index 
of anxiety-like and risk-taking behavior. 
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Acoustic startle test.  This procedure is based on the reflexive whole-body flinch, or startle 
response, that follows exposure to a sudden noise.  Measures are taken of prepulse 
inhibition, which occurs when a weak prestimulus leads to a reduced startle in response to 
a subsequent louder noise.  Subjects were tested with a San Diego Instruments SR-Lab 
system.  Briefly, mice were placed in a small Plexiglas cylinder within a larger, sound-
attenuating chamber.  The cylinder was seated upon a piezoelectric transducer, which 
allowed vibrations to be quantified and displayed on a computer.  The chamber included a 
ceiling light, fan, and a loudspeaker for the acoustic stimuli.  Background sound levels (70 
dB) and calibration of the acoustic stimuli were confirmed with a digital sound level meter 
(San Diego Instruments). 
The test began with a 5-min habituation period, followed by 42 trials.  There were 7 
different types of trials:  the no-stimulus trials, trials with the acoustic startle stimulus (40 
msec; 120 dB) alone, and trials in which a prepulse stimulus (20 msec; either 74, 78, 82, 86, 
or 90 dB) occurred 100 ms before the onset of the startle stimulus.  An overall analysis was 
performed for each subject's data for levels of prepulse inhibition at each prepulse sound 
level (calculated as 100 - [(response amplitude for prepulse stimulus and startle stimulus 
together / response amplitude for startle stimulus alone) x 100]. 
 
Wire-hang test for grip strength.  At the start of the test, the mouse was placed on a large 
metal cage lid.  The lid was gently shaken to induce the mouse to grip onto the metal grid.  
The cage top was then flipped over, and latency for the mouse to fall from the lid was 
recorded during the 60-sec test. Measures were also taken for coordination of movement 
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on the wire grid, using the scoring system adapted from a screen developed by William 
Wetsel, Ph.D., and Ramona Rodriguez, Ph.D., Duke University, Durham, NC. 
 
Rotarod test.  Subjects were tested for motor coordination and learning on an accelerating 
rotarod (Ugo Basile, Stoelting Co., Wood Dale, IL).  For the first test session, animals were 
given three trials, with 45 seconds between each trial.  An additional trial was given 48 
hours later.  Rpm (revolutions per minute) was set at an initial value of 3, with a 
progressive increase to a maximum of 30 rpm across 5 minutes (the maximum trial length).  
Measures were taken for latency to fall from the top of the rotating barrel.   
 
Kainic acid treatment. P30-P40 wildtype and miR-29Nestin animals were injected 
intraperitoneally with 30 mg/kg of kainic acid (Sigma, catalog # K0250) in order to induce 
seizures. Seizures were scored according to Racine’s seizure activities score(Morimoto et 
al. 2004).  
 
microRNA qRT-PCR analysis. RNA was extracted from cerebella and cortices using the 
Qiagen miRNeasy kit (catalog #217004) using the manufacturer’s instructions. Mature 
miR-29 expression was assayed using TaqMan MicroRNA Assays (Applied Biosystems). 
Briefly, 10 ng of RNA was reverse transcribed using Superscript III reverse transcriptase 
(Invitrogen) and specific RT primers for miR-29a, miR-29b, miR-29c and U6 RNA (Applied 
Biosystems).  Reactions were amplified in an ABI7500 system and relative quantification 
was carried out using the delta delta Ct method. Sample variability was corrected by 
normalizing to U6 RNA levels. 
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cDNA synthesis and qRT-PCR analysis. For analysis of Dnmt3a mRNA, cDNA library was 
prepared synthesized using 500 ng RNA. RNA samples were first treated with RQ1 DNase 
(Promega) for 30 min at 37C followed by a 10 min incubation at 65C with DNase Stop 
Solution (Promega). DNase-treated RNA was mixed with 0.25 g random hexamer primers 
(Invitrogen) and reverse transcribed using Superscript III reverse transcriptase 
(Invitrogen) according to the manufacturer’s instructions. Each 25 L PCR reaction 
contained 1 L cDNA, each primer at a final concentration of 400 nM, and Power SYBR 
Green PCR Master Mix (Applied Biosystems). Reactions were amplified in an ABI7500 
system and relative quantification was carried out using the delta delta Ct method. Sample 
variability was corrected by normalizing to GAPDH levels. 
 
Western blotting.  Whole cortices were lysed by homogenization in RIPA buffer. Protein 
concentrations were quantified using the Bicinchoninic acid method (Thermo Scientific), 
and equal concentrations of protein were resolved on SDS-polyacrylamide gels and 
transferred onto PVDF membranes. The Dnmt3a (Abcam) and β-actin (Sigma) primary 
antibodies were used. Antibody conjugates were visualized by chemiluminescence (ECL; 
Amersham Life Science). Images were quantified using ImageJ software. 
 
Immunohistochemistry.  For immunohistochemistry experiments, mice were 
anesthetized using isoflurane and transcardially perfused with 4% paraformaldehyde. The 
mice were then decapitated, and the brains were post-fixed in 4% paraformaldehyde 
overnight. Paraffin-embedded sections were used for hematoxylin-eosin (H/E), cleaved 
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caspase-3 and NeuN stains. Briefly, IHC was carried out in the Bond Autostainer (Leica 
Microsystems Inc. Norwell, MA 02061). Slides were dewaxed in Bond Dewax solution 
(Leica, part #AR9222) and hydrated in Bond Wash solution (Leica, catalog #AR9590). 
Antigen retrieval was performed for 30 min at 100ºC in Bond-Epitope Retrieval solution 1 
pH-6.0 (AR9961).  Slides were incubated with the cleaved caspase-3 and NeuN primary 
antibodies for 1 hour. DAPI was used as a nuclear stain. Antibody detection was performed 
using the Bond Polymer Refine Detection System (DS9800). Stained slides were 
dehydrated and coverslipped. Representative images are obtained from independent 
experiments, done at least in triplicate.  
 
For all other stains, P40 wildtype and miR-29-deficient brains were embedded in 4% low-
melting-point agarose in 1x PBS and were sectioned coronally (50 µm) on a vibratome 
(Leica VT 1200S). The following antibodies were used for immunohistochemistry: NeuN 
(catalog #MAB377, Millipore), Cux-1 (catalog #SC13024, Santa Cruz Biotechnology), 
calretinin (catalog #ab702, Abcam), calbindin (catalog #2173, Cell Signaling), GABA 
(catalog #A2052, Sigma). Appropriate anti-mouse, anti-rabbit, anti-rat, or anti-guinea pig 
secondary antibodies were used to detect primary antibody binding. DAPI was used as a 
nuclear stain. Representative images are obtained from independent experiments, done at 
least in triplicate.  
 
Slice electrophysiology. Slice electrophysiology experiments were conducted and 
analyzed similarly to those published previously(Sparrow et al. 2012). Briefly, mice were 
rapidly decapitated under isoflurane anesthesia, and 300uM coronal slices containing the 
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dorsolateral striatum (DLS) were prepared on a vibratome (Leica VT1200). Extracted 
brains were placed in ice-cold modified high sucrose artificial cerebrospinal fluid (aCSF) 
containing the following (in mM): 194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 
NaH2PO4, 10.0 glucose, and 26.0 NaHCO3. Slices were then transferred to normal aCSF 
maintained at approximately 30 degrees (Warner Instruments, Hamden, Connecticut) 
containing the following (in mM): 124 NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 
glucose, and 26.0 NaHCO3. Slices were placed in a holding chamber (Warner Instruments, 
Hamden, CT), and were allowed to rest for one hour, and remained there until used. Slices 
were continuously bubbled with a 95% O2 / 5% CO2 mixture throughout slicing and 
experiments.  Thin-walled borosilicate glass capillary recording electrodes (3–6 MΩ) were 
pulled on a Flaming-Brown Micropipette Puller (Sutter Instruments). Following rupture of 
the cell membrane, cells were allowed to rest and equilibrate to the intracellular recording 
solutions (below). Input resistance was monitored continuously throughout the 
experiment, and when input resistance deviated by more than 20% the experiment was 
discarded.  Current clamp experiments were conducted to assess intrinsic neuronal 
excitability and current-injected firing of OFC pyramidal neurons, identical to those 
published previously(Pleil et al.). Experiments were conducted using a potassium-
gluconate based internal containing the following (in mM): K-gluc, 5 NaCl, 2 MgCl2, 10 
HEPES, 0.6 EGTA, 4 Na2ATP, 0.4 Na2GTP. Experiments were conducted both at resting 
membrane potential (RMP) and -70mV. The experimenter was blinded to mouse genotype 
until after data analysis. 
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Statistics. Statistical analyses were performed using GraphPad Prism 5 software. Data are 
obtained from at least three independent experiments and expressed as mean ± s.e.m. 
unless otherwise specified. The Student’s t-test (unpaired, two-tailed) for parametric data 
was used for analysis of two groups. No statistical methods were used to predetermine 
sample sizes, but our sample sizes are consistent with those reported in previous 
publications. 
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3.6 Figures and Legends            
     
Figure 3.1: Potential microRNA binding sites in the 3' UTR of mouse Dnmt3a. 
 
Analysis of the 3' UTR of mouse Dnmt3a for potential miRNA binding sites (www.targetscan.org). 
Asterisk denotes miRNAs with more than one binding site.  miR-29 is highlighted in red.  
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Figure 3.1 
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Figure 3.2: Cerebellar granule neural precursor cells complete their differentiation  
into cerebellar granule neurons by P18.  
 
Cerebella from P7 and P18 were co-stained with PCNA (red), a marker of proliferation, and 
p27 (green), a marker of differentiation. Scale bar denotes 200 µm.  
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Figure 3.2 
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Figure 3.3: miR-29 upregulation is essential for brain maturation.  
 
(A) Small RNA-sequencing of young (P18) and adult (P250) differentiated mouse cerebella reveals 
miR-29 as the most upregulated miRNA family. Quantitative PCR analysis for miR-29b in mouse 
cerebellum (B) and cortex (C) at different ages. Data shown are means ± s.e.m. for each group; ** P 
< 0.01. (D) WT and miR-29CMV mice at P10 and P28. Body weights (males) (E) and Kaplan-Meier 
survival curve (F) for WT and miR-29CMV mice. (G) WT and miR-29Nestin mice at P10 and P28. Body 
weights (males) (H) and Kaplan-Meier survival curve (I) for WT and miR-29Nestin mice. 
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Figure 3.3 
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Figure 3.4: Generation of miR-29 mice. 
 
(A) PCR genotyping (toe clips) for the floxed (f) and wildtype (w) bands in miR-29ab1f/f CMV-Cre-; 
miR-29ab1f/+ CMV-Cre+; miR-29ab1f/f CMV-Cre+ mice. Note the disappearance of the miR-29ab1 
band in the miR-29ab1f/f CMV-Cre+ sample. (B) Quantitative PCR analysis for all three family 
members of miR-29 from the cortex of WT and miR-29CMV mice at P30. (C) PCR genotyping for 
floxed and wildtype bands in WT, miR-29ab1f/+ Nestin-Cre+ and miR-29ab1f/f Nestin-Cre+ mice. 
Similar PCR genotyping for miR29b2c loci is shown in (D). (E) Quantitative PCR analysis for all 
three family members of miR-29 from the cortex of WT and miR-29Nestin mice at P40. L = ladder; f 
= floxed; w = wildtype.  
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Figure 3.4 
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Figure 3.5:  Kaplan-Meier survival curve of mice partially deleted for miR-29 shows 
 
dose-dependent effect. 
 
Kaplan-Meier survival curves of miR-29 WT, miR-29 abf/+ bcf/f and miR-29 abf/f bcf/+ mice. 
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Figure 3.5 
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Figure 3.6: miR-29-deficient mouse brains appear grossly normal. 
 
Hematoxylin and eosin (H/E) stains of representative wildtype, miR-29CMV and miR-29Nestin 
mouse sagittal brains at P30.  
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Figure 3.6 
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Figure 3.7: miR-29-deficient mouse brains do not exhibit increased apoptosis.  
 
Representative images of wildtype, miR-29CMV and miR-29Nestin mouse cortex (A) and 
hippocampus (B) stained with cleaved caspase-3 (green), NeuN (red). 
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Figure 3.7 
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Figure 3.8: Orbitofrontal cortex (OFC) pyramidal neurons did not differ in basic 
properties of intrinsic excitability or current-injected firing. 
 
(A) WT and miR-29Nestin mice had similar resting membrane potentials (RMPs).  (B) There were 
no differences seen in the rheobase, the minimum amount of current required to fire an action 
potential (AP) at either RMP or -70mV. WT = wildtype; KO = miR-29Nestin mice. (C) No differences 
were observed in the action potential threshold, the membrane potential at which the first action 
potential fired, at either either RMP or -70mV. The current-injected firing at RMP or -70mV was 
similar between wildtype and miR-29Nestin mice (D, E).  n.s. = not significant (p>0.05). 
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Figure 3.8 
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Figure 3.9: Bisulfite sequencing and gene array analysis reveal non-canonical DNA  
methylation and dysregulation of synapse-associated pathways in the miR-29Nestin  
brain. 
 
(A) Quantitative PCR analysis for Dnmt3a in the cortex of WT and miR-29Nestin mice at P40. Data 
shown are means ± s.e.m. for each group; ** P < 0.01. (B) Western blot analysis of Dnmt3a levels in 
cortices from P40 WT and miR-29Nestin mice. (C) Genome-wide non-CG methylation levels of 
cortices from P40 WT and miR-29Nestin mice (n=4 WT and n=4 miR-29Nestin mice). (D) mCH 
increase in miR-29Nestin cortices compared to WT occurs at sites normally CH methylated.  mCH 
levels (of 4 WT and 4 miR-29Nestin mice) were calculated in 5 kb tiles across the genome and 
ranked by previously reported 6 week frontal cortex mCH levels (x-axis) (Lister et al., 2013). The 
average mCH levels in WT and miR-29Nestin  within 2000 tiles were calculated (y-axis). Tiles with 
low coverage in the frontal cortex data (Lister et al., 2013) were removed ((#C+#T)<100).  (E) 
Gene array analysis from the cortices of P40 WT and miR-29Nestin mice reveal a total of 444 
significantly altered genes (226 upregulated genes, 218 downregulated genes) in the miR-29Nestin 
mice. Analysis was conducted on n=3 WT and n=3 miR-29Nestin mice.  (F) Statistically significant 
enrichment of miR-29 target sites among the highly upregulated genes in the miR-29Nestin mice 
using miRHub analysis.  (G) Heatmaps for synapse-associated genes between WT and miR-29Nestin 
mice reveal significant downregulation of these genes in the miR-29-deficient brain. Disease 
associations for each downregulated gene are listed at right. Red denotes significantly upregulated 
genes and green denotes significantly downregulated genes.  (H)  mCH levels of the representative 
repressed neuronal genes in wildtype and miR-29Nestin mice.  Data shown are means ± s.e.m. for 
each group; * P< 0.05, ** P < 0.01. 
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Figure 3.10: miR-29 deficiency in the brain results in upregulation of the Dnmt3a  
 
and the Wnt/-catenin pathway. 
 
(A) Gene array heatmap of Dnmt3a in the cortex, hippocampus and striatum of WT and miR-
29Nestin mice reveals significant upregulation of Dnmt3a in the miR-29-deficient brain.  (B) Gene 
array heatmap of genes in the Wnt/β-catenin pathway between WT and miR-29Nestin mice reveal 
significant upregulation of these genes in the miR-29-deficient brain. 
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Figure 3.10 
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Figure 3.11: CG methylation is unaltered in miR-29Nestin mice. 
 
Genome-wide CG methylation levels of cortices from P40 WT and miR-29Nestin mice. 
  
 127 
 
Figure 3.11 
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Figure 3.12: Altered excitatory/inhibitory balance in miR-29Nestin mice leads to 
increased susceptibility to tonic-clonic seizures. 
 
(A-D) Decreased number of inhibitory interneurons observed throughout the cortex of P40 
miR-29Nestin mice.  (E) miR-29Nestin mice show a significant increase in the number of Cux1-
positive neurons in the cortex. Data shown are means ± s.e.m. for each group. * P < 0.05 and 
** P < 0.01.  (F) miR-29Nestin mice injected with kainic acid display Racine seizure scale 
characteristics much earlier compared to WT animals.  (G) miR-29Nestin mice are 
significantly more susceptible to undergoing tonic-clonic seizures and subsequent death 
with kainic acid compared to WT. Data shown are from n= 4 WT and n=6 miR-29Nestin mice.  
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Figure 3.12 
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Figure 3.13: miR-29-deficient mice display excessive self-grooming, facial lesions 
and neurobehavioral abnormalities. 
 
(A-B) miR-29Nestin mice exhibit significantly greater periods of time undergoing hindlimb 
clasping upon tail suspension. Analyses were conducted on P30 mice. miR-29-deficient 
mice display severe facial lesions (C, D) and spend significantly greater periods of time 
grooming compared to wildtype (E). 60-minute open field analyses reveal that miR-29Nestin 
mice travel greater distances (F), exhibit greater numbers of fine movements (G), and 
spend more time in the center region (H) compared to wildtype animals. (I) Reduced 
prepulse inhibition in miR-29Nestin mice. Data shown are means ± s.e.m.  miR-29Nestin mice 
have significantly reduced grip strength (J) and reduced latency to fall on the accelerating 
rotarod (K).  B,E, ** P < 0.01. F-K, * P < 0.05, post-hoc test following repeated measures 
ANOVA. 
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Figure 3.13 
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Figure 3.14: Whole-body deletion of miR-29 leads to facial and dorsal body lesions. 
 
Photos of miR-29CMV double knockout (A) and single knockout (B) mice showing extensive 
facial and dorsal body lesions resulting from excessive self-grooming.  
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Figure 3.14 
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CHAPTER FOUR:  DISCUSSION 
 
 
5.1 Part I: Summary of findings, clinical relevance and future directions 
 
 
Bcl-xL is essential for the survival and function of differentiated neurons in the cortex that 
control complex behaviors: 
 
Every neuron in the brain undergoes different phases or stages throughout the life 
of an organism. The life cycle of a neuron starts with the generation of neuronal 
progenitors from pluripotent stem cells (Kriegstein et al. 2006). These mitotically active 
neuronal progenitor cells go on to differentiate into early postmitotic neurons before they 
migrate to their eventual destinations in the brain (Kriegstein and Alvarez-Buylla 2009; Lui 
et al. 2011). More importantly, these immature neurons undergo a phenomenon known as 
maturation in the early postnatal to adolescent period to become mature neurons, during 
which new synapses are made and the synaptic connections between neurons are scaled 
back and refined.  This stage of brain maturation ensures the development of a properly 
formed brain which, during old age, undergoes degeneration. 
It is widely accepted that the apoptotic machinery is strictly regulated during the 
period of neurogenesis in the brain. In fact, all of the mice deficient in the apoptotic 
machinery (e.g. Apaf-1, Caspase-3, Caspase-9) display severe consequences during the peak 
of neurogenesis in which the precursors that normally undergo physiological cell death 
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continue to persist in these mutant mice (Kuida et al. 1996; Cecconi et al. 1998; Hakem et 
al. 1998; Kuida et al. 1998; Woo et al. 1998; Yoshida et al. 1998).  This persistence of 
mitotically active precursor cells results in either embryonic or perinatal lethality. These 
findings highlight the importance of physiological cell death in which the brain generates 
more precursors than needed in order to kill the extra neuronal precursors and suggest 
that the cell death pathway is most crucial during the period of embryonic development. 
Indeed, much of the literature focuses on the requirement of the apoptotic pathway before 
the period of differentiation. Here, we found that the reliance of the brain on the apoptotic 
machinery is not restricted to neuronal precursors in the embryonic brain but instead also 
extends to early postmitotic neurons. In particular, the neurons that are critical for 
governing certain higher order functions are acutely dependent on Bcl-xL for their survival. 
The main findings of this work are summarized below: 
 
1. Programmed cell death in the brain during the embryonic as well as early postnatal 
periods is tightly regulated by the anti-apoptotic protein Bcl-xL. 
2. Neural precursor cells in the brain express very low levels of Bcl-xL and are 
resistant to cell death upon deletion of the gene. 
3. In contrast, early differentiated neurons are acutely dependent on Bcl-xL for their 
survival. Deletion of Bcl-xL in the neural precursor cells results in a marked increase 
in cell death in the neurons of the brains of early postnatal mice. 
4. Upper layer cortical neurons are more vulnerable to Bcl-xL deletion compared to 
deeper layer neurons, suggesting that Bcl-xL has a role in the survival of specific 
postmitotic neurons in the developing brain. 
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5. The cell death induced by loss of Bcl-xL can be rescued by co-deletion of the pro-
apoptotic proteins Bax and Bak. 
6. Deletion of Bcl-xL exclusively in postmitotic neurons results in a similar pattern of 
cell death and also has a significant effect on the body size of these mice. 
7. Importantly, Bcl-xL deletion in the brain led to severe behavioral and cognitive 
deficits, implicating the role of Bcl-xL in the survival of neurons that are involved in 
higher order brain functions. 
 
Clinical relevance:  
 
While physiological cell death is critical for proper brain development, dysregulated 
apoptosis that occurs after the brain is fully developed could lead to severe defects. Indeed, 
cell death proteins have been implicated in multiple neurodegenerative disorders including 
Alzheimer’s, Parkinson’s and Huntington’s disease (Mattson 2000).  We recently conducted 
a gene array analysis of the cortices isolated from wildtype and Bcl-xL-deficient mice to 
study gene-disease associations. Using GSEA (Gene Set Enrichment Analysis, Broad 
Institute), we identified the gene sets that are highly upregulated or downregulated upon 
deletion of Bcl-xL in the brain. Interestingly, the disease pathway that is most significantly 
associated with Bcl-xL deletion in the brain is the set of genes downregulated in 
Alzheimer’s disease. This finding suggests that Bcl-xL deficiency could play a major role in 
the pathogenesis of Alzheimer’s disease.  The data could be used not only for the 
therapeutic potential of Bcl-xL in neurodegenerative disease but could also reveal the 
downstream effectors of Bcl-xL in the brain. Another exciting finding of our study is an 
unexpected role of Bcl-xL in preventing compulsive overgrooming and the resultant self-
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inflicted lesions. While the role of Bcl-xL in cell death is well studied and uncontroversial, 
its function in controlling complex behaviors is surprising but exciting.  
 
Future directions: 
 
While our results on the consequence of Bcl-xL deletion in the brain in vivo are 
striking and somewhat surprising, these findings also pave the path for exciting 
prospective studies. For example, why are early differentiated neurons more sensitive to 
loss of Bcl-xL compared to neuronal precursors and mature neurons? While physiological 
apoptosis is known to be activated in rapidly dividing neuronal precursor cells during 
embryonic development, these cells do not express high levels of Bcl-xL and thus do not 
appear to be acutely dependent on Bcl-xL for their survival.  In contrast, Bcl-xL becomes 
highly expressed in the neurons that differentiate from these precursor cells, possibly as a 
result of increased energetic dependence on the mitochondria in postmitotic neurons. 
Indeed, Bcl-xL is tightly associated with the mitochondria as discussed below.  As neurons 
become mature, multiple apoptotic brakes are activated, making mature neurons resistant 
to loss of Bcl-xL. Indeed, we can test this hypothesis by culturing neuronal precursor cells, 
differentiating these cells into neurons, maturing them in culture, and testing the 
sensitivity of these cells to apoptosis by inhibiting various cell death genes.  
Another possible reason for the dependency on Bcl-xL could be due to a non-
apoptotic role of Bcl-xL in early differentiated neurons but not in precursors and late 
differentiated neurons. Indeed, multiple labs have shown that Bcl-xL plays an important 
role in mitochondrial respiration and in the F1F0 ATPase (Alavian et al. 2011; Chen et al. 
2011). Because of our discovery that Bcl-xL is most critical during early differentiation, 
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future studies showing that mitochondrial respiration is most sensitive during this stage 
(as compared to neuronal precursors and/or mature neurons) could be very informative 
for the field of neurodevelopment. Indeed, neurons are generally believed to rely more on 
glycolysis than on oxidative phosphorylation, and it is possible that, during this shift from 
oxidative phosphorylation to glycolysis, there is a vulnerable period when neurons are 
acutely dependent on ox-phos for their survival.  
Finally, the unexpected finding of the role of Bcl-xL in governing complex higher 
order behaviors should be studied in detail in the future. By utilizing the Bcl-xLf/f Baxf/f Bak-
/- Nex-Cre triple knockout mice, we can examine whether the behaviors observed the mice 
deleted for Bcl-xL is mediated via its apoptotic or non-apoptotic role.  Thus, if the triple 
knockout mice still exhibit similar neurobehavioral deficits such as hyperactivity and self-
injurious and risk-taking behaviors, this points to a non-apoptotic role of Bcl-xL in 
regulating these behaviors, possibly through its synaptic functions.  
 
5.2 Part II: Summary of findings, clinical relevance and future directions 
 
 
MicroRNA-29 is an essential regulator of DNA methylation during brain maturation: 
 
After a neuron has differentiated, it undergoes a period of maturation. Surprisingly, 
this period in the life cycle of a neuron has not been studied in detail, perhaps because of 
the belief that an early or immature postmitotic neuron has similar physiological 
properties to a mature differentiated neuron. Recently, however, neuroscientists have 
taken a keen interest in the period of brain maturation and have recognized that dynamic 
changes occur during this stage, including processes such as synaptogenesis and 
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subsequent pruning of the synapses to maintain proper connections between neurons.  
Here, we found that the period of maturation from a young neuron to a mature neuron is 
critical for the identity and proper function of a neuron during adulthood. Collectively, this 
maturation process is essential for homeostatic control in the brain. While many genes and 
pathways are likely involved in this process, we identified a single microRNA known as 
miR-29 which, in turn, can modulate multiple pathways during maturation. Nevertheless, it 
is not surprising that miR-29 also plays other roles during neuronal maturation, such as 
restricting the apoptotic pathway in mature neurons to maintain their long-term survival. 
The main findings of this work are summarized below: 
 
 
1. The microRNA-29 (miR-29) family is induced specifically during the period of brain 
maturation. 
2. Deletion of all the three members of the miR-29 family, both globally or 
conditionally in the brain, leads to post-natal lethality at approximately P30. 
3. miR-29-deficient mice exhibit several neurological deficits including hindlimb 
clasping, motor deficits, hyperactivity as well as risk-taking behaviors. These mice 
also exhibit repetitive behaviors including compulsive overgrooming that leads to 
facial ulcers and bleeding. 
4. Mice deleted for miR-29 are hypersociable in the three-chamber sociability test. 
5. These mice also show an excitatory/inhibitory (E/I) imbalance that leads to 
increased susceptibility to seizures and status epilepticus following kainic acid 
injection.  
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6. DNA methylation plays an important role during brain maturation, and miR-29 
targets a critical protein of the pathway Dnmt3a. Consistently, brain deleted for 
miR-29 show increased levels of Dnmt3a. 
7. Bisulfite sequencing of miR-29-deficient mice shows hypermethylation of genes 
throughout the brain. Interestingly, this hypermethylation occurs in a non-CG 
context (also referred to as CH methylation). 
8. Gene array and RNAseq analysis of these mice revealed multiple downregulated 
genes that are critical for neuronal function. Additionally, many of these genes have 
a direct association with autism spectrum disorders. 
9. Indeed, gene association studies showed significant overlap in genes downregulated 
in miR-29 KO brain and in human ASD brain. 
10. Long neuronal genes are specifically downregulated in the miR-29-deleted brain. 
This phenomenon has also been recently reported to occur in the brains of ASD 
patients. 
 
Clinical relevance: 
 
According to data in 2014 from the Centers for Disease Control, 1 in every 68 
children is currently diagnosed with autism spectrum disorder (ASD) in the United States. 
Multiple gene association studies have failed to pinpoint a single causative gene for ASD. 
This led to the consensus that there should be increasing focus be on multiple genes and 
pathways rather than a single gene (Abrahams and Geschwind 2008). Similarly, there has 
been considerable attention on the role of epigenetics as the underlying cause of ASD 
(Schanen 2006; Siniscalco et al. 2013). 
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The miR-29 family of microRNAs could be critical in the pathogenesis of ASD as it 
plays an essential role in regulating DNA methylation across the mammalian genome. First, 
because of its ability to target the 3’UTR of multiple genes, miR-29 can regulate multiple 
pathways that play a role in ASD.  More importantly, we have shown in our study that miR-
29 targets the DNA methyltransferase Dnmt3a and decreases gene expression throughout 
the genome via hypermethylation of these genes. This finding is underscored by the fact 
that most of the genes that are downregulated in the miR-29-deficient brain are associated 
with neuronal functions that are directly implicated in ASDs and other 
neurodevelopmental disorders.  Therefore, our study lays the foundation for exciting 
clinically relevant studies whereby miR-29 could be developed as a small molecule therapy 
for ASDs and related neurodevelopmental disorders. The notion of increasing the levels of 
an endogenous gene rather than treating a subject with an exogenous chemical is 
preferable and avoids potential immune reactions or rejections. Further, our gene 
association study has revealed that ASD brains are similar to the brains of miR-29-deficient 
brains. Thus, therapies could be aimed at increasing the miR-29 levels in ASD patients to 
physiological levels rather than to artificial levels that could have potential off-target 
effects of expressing too high levels of miR-29. 
Moreover, one of the reasons our lab initially became interested in miR-29 was our 
discovery than miR-29 can prevent apoptotic cell death in sympathetic neurons. In fact, our 
lab has been granted a patent for the role of miR-29 in neuronal protection. In addition, 
multiple labs have shown miR-29 levels to be decreased in Alzheimer’s, Parkinson’s and 
Huntington’s disease brains. Therefore, miR-29 could be also tested as a small molecule 
therapy in patients with neurodegenerative diseases. In fact, GSEA (Gene Set Enrichment 
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Analysis, Broad Institute) analysis showed a commonality between genes downregulated in 
miR-29-deleted brains and those downregulated in the brains of Alzheimer’s disease 
patients, thus suggesting a common etiological role.  
 
Future directions: 
 
While the above proposed clinical studies are directly relevant to both ASDs as well 
as neurodegenerative diseases and could lead to clinical trials testing the therapeutic 
potential of miR-29, our present study also lays the foundation of exciting research to 
further our understanding of neurodevelopment, neuronal maturation and 
neurodegeneration. We expect a subset of the phenotypes of the miR-29-deficient mice to 
be a result of Dnmt3a overexpression. As a consequence of overexpression of Dnmt3a, we 
also expect a global hypermethylation of genes in the brain. To accurately define the exact 
phenotypes that are mediated by Dnmt3a (and hypermethylation) versus those that are 
independent of Dnmt3a, we are currently crossing our miR-29-deficient mice with mice 
that are conditionally deleted for Dnmt3a.  Once these miR-29/Dnmt3a-deficient mice are 
generated, we plan to characterize the phenotypes of these mice using behavioral tests (e.g. 
open field analysis), three-chamber social interaction tests, RNAseq and bisulfite 
sequencing analysis to assess which phenotypes are rescued in the miR-29/Dnmt3a 
double-deficient mice.   
To complement this genetic experiment, we are also generating transgenic mice that 
conditionally overexpress Dnmt3a. Surprisingly, we are not aware of any lab that has 
generated a mouse model overexpressing Dnmt3a to date. Here, we hypothesize that these 
mice will phenocopy the mice that are deleted for miR-29 in the brain. In addition to the 
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neurobehavioral experiments outlined above, we will assess the ASD phenotypes that are 
directly related to epigenetics (e.g. hypermethylation).  Finally, to accurately define the 
relationship between miR-29 and Dnmt3a, we are generating a new mouse model in which 
the endogenous Dnmt3a is modified such that the miR-29 binding sites along the 3’UTR are 
abolished.  These three novel mouse models will serve as excellent tools in the future to 
study the relationship between miR-29, Dnmt3a and ASD. 
Furthermore, deciphering the neuronal subtypes that are responsible for the 
neurobehavioral phenotype of the miR-29-deficient mice is also important. Here, we show 
that deletion of miR-29 leads to an increase in the number of excitatory projection neurons 
and a reduction in the number of inhibitory interneurons, thus leading to an E/I imbalance 
and shifting the brain towards an excitatory phenotype. In fact, studies have found that, in 
the cortex of patients with ASD there is increased neuronal diversity and neuronal 
numbers as compared to the brains of control subjects (McCaffery and Deutsch 2005; 
Casanova et al. 2006; Courchesne et al. 2011). In addition, mutations in the Shank3 gene 
are known to lead to autism and ASD-like phenotypes in mice (Durand et al. 2007; Peca et 
al. 2011). Mice deficient in Shank3 were shown to exhibit cortical hyperactivity during the 
early postnatal period (Peixoto et al. 2016), while Takao Hensch’s group found a reduction 
in the number of parvalbumin-expressing neurons in the cortex of these mice (Gogolla et al. 
2014).  Huda Zoghbi’s group has also found a link between Shank3 and abnormal 
excitatory and inhibitory synapses, where overexpression or duplication of Shank3 was 
found to result in a hyperkinetic disorder with manic-like behavior and seizures that were 
attributed to an E/I imbalance in the brain (Han et al. 2013).  
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Recently, there has also been a push to link the behavior of mice to the specific 
neuronal subtypes present within the brain. For example, Nancy Ip’s group recently found 
that an in utero intraventricular injection of the small molecule XAV939, which increases 
the intermediate progenitor population in the brain to generate more pyramidal neurons in 
layers II/III of the cortex, led to an E/I imbalance in the brain and resulted in behaviors that 
resembled what is observed in patients with autism, including repetitive self-grooming 
behavior, deficits in social interaction, and repetitive digging behavior on the marble 
burying test (Fang et al. 2014). 
To determine the precise role of excitatory versus inhibitory neurons, we crossed 
the miR-29 floxed mice with a mouse expressing the Nex-Cre transgene (these mice 
referred to as miR-29Nex), which recombines exclusively in the postmitotic excitatory 
projection neurons that spares recombination in the inhibitory interneurons. We also 
generated mice in which miR-29 was recombined in the inhibitory interneurons using the 
Parvalbumin-Cre line (thus sparing the excitatory projection neurons; these mice are 
referred to as miR-29Parvalbumin). Interestingly, our preliminary data shows that miR-29Nex 
mice show similar repetitive grooming and resultant facial ulcers as seen in the miR-29Nestin 
mice. Further, miR-29Nex mice die by P90, suggesting that many of the miR-29 knockout 
phenotypes are driven by the loss of miR-29 in the excitatory projection neurons. The miR-
29Parvalbumin mice appear grossly normal. However, to specifically probe the role of the 
excitatory versus inhibitory interneurons in the phenotype of the miR-29-deficient mice, a 
detailed neurobehavioral analysis as described for the miR-29Nestin mice must be 
conducted. 
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5.4 Concluding remarks 
 
The mystery behind the brain is slowly unravelling. However, the enigma of the 
brain continues to surprise us and excite us even after more than 100 years Ramon y Cajal, 
the father of modern neuroscience, identified multiple neurons and pathways in the brain. 
For example, the field of optogenetics rapidly emerged in the last five years identifying new 
pathways and functions of parts of brain challenging previous known knowledge about 
those pathways. During my time in graduate school, I was fortunate to study two distinct 
but important phases in neuron life cycle. The work presented here and by others 
demonstrates that neuronal survival during early embryonic and postnatal development 
and the maturation of and long-term survival of neurons in the brain are mediated by 
multiple, complex mechanisms that involve anti-apoptotic proteins and microRNAs. 
Further investigation of the mechanistic insights into how these players mediate critical 
events in the brain will drive the generation of targeted therapeutics for patients suffering 
from many of the neurodevelopmental and psychiatric disorders that are seen today. The 
coming years in neuroscience will be an exciting field for neuroscientists. 
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